The prevalence of breast cancer in Africa and establishment of The Libyan Breast Cancer Registry by Abulkasim, Muna Abdussalam Owen
THE PREVALENCE OF BREAST CANCER IN AFRICA AND 
ESTABLISHMENT OF THE LIBYAN BREAST CANCER 
REGISTRY 
  Muna Abdussalam Owen Abulkasim 
   ABLMUN001 
 Dissertation presented for the degree of Master of Science 
 University of Cape Town 
 Supervisor 
Mark E. Engel 
Denver Hendricks 
  Leila Abdullahi 
Liesl Zühlke 




















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 














The copyright of this thesis vests in the author. No quotation from it or information 
derived from it is to be published without full acknowledgement of the source. The thesis 
is to be used for private study or non-commercial research purposes only.  
Published by the University of Cape Town (UCT) in terms of the non-exclusive license 






























I, Muna A O Abulkasim, hereby declare that the work I have submitted is based on my 
own original work and has not, in whole or in part, been submitted towards another degree 
at this university or elsewhere. Where the work of others has been used (whether quoted 
verbatim, paraphrased, or referred to) it has been attributed and acknowledged. 
I empower the university to reproduce for the purpose of research either the whole or any 
portion of the contents in any manner whatsoever. 
Signature: 
Date: February 2020 
Acknowledgements:  
I would like to express my thanks and appreciation to all those who have supported me in 
my journey and made it possible.   
 
My supervisors: Mark Engel, Leila Abdulhi, Denver Hendricks and Liesl Zühlke. For 
passing their valuable experience. Thank you for your support, positivity, and 
encouragement. 
 
I would like to thank the University of cape Town staff members for giving this 
opportunity. Special thanks to library members Namhla Madini, Wendy Smith and 
Tamzyn Suliman without their enormous effort in gathering all required reference it 
would not been possible.   
 
My supportive and loving husband Salah and my two wonderful children Helana and 
Adam which I hope to set an inspiring example in their life. 
 
Lastly, I would like to thank my parents for their patients and constant prays. 
 
Table of contents: 
 
Declaration  i 
Acknowledgments ii 
Abstract  iii 
  
Chapter One: Introduction to my thesis 1 
  
Chapter Two: Literature review 1 
2.1 Introduction 2 
2.2 Breast Cancer Milestones 2 
2.3 Common types of breast tumors  4 
2.4 Global Burden 8 
2.4.1 Breast cancer burden: Africa 9 
2.5 Risk factors of breast cancer 11 
2.6 Screening for breast cancer 15 
2.7 Types of biopsies 19 
2.8 Treatment 21 
2.9 Breast cancer and pregnancy 23 
2.10 Male breast cancer 24 
2.11 Prevention and conclusion 25 
2.12 Chapter two References  27 
  
  
Chapter Three: The Prevalence of Breast Cancer in Africa: A Systematic Review Study Protocol 1 
3.1 Background 2 
3.2 Objectives 3 
3.3 Review question 3 
3.4 Selecting studies for inclusion 6 
3.5 Quality appraisal of included studies 6 
3.6 Data extraction and management 6 
3.7 Data synthesis including assessment of heterogeneity 7 
3.8 Assessment of reporting biases 7 
3.9 Reporting of this review 8 
3.10 Ethics and Dissemination 8 
3.11 Chapter Three References 9 
3.12 Appendix 11 
  
 Chapter Four: Methods, Results and Conclusion Systematic Review 1 
Abstract 4 
4.1 Introduction 4 
4.2 Aim 4 
4.3 Methods 5 
4.3.1 Criteria for included studies 5 
4.3.2 Search strategy for identification of relevant studies 6 
4.3.3 Data extraction and management 7 
4.3.4 Selecting studies for inclusion 7 
4.3.5 Quality appraisal of included studies 7 
4.3.6 Data synthesis including assessment of heterogeneity 8 
4.4 Results  8 
4.5 Discussion 25 
4.6 Conclusion and Recommendations 28 
4.7 Ethics and Dissemination 28 
4.12 Chapter Four References 30 
4.13 Appendix  33 
  
Chapter Five: LBCR  1 
5.1 Cancer Registries 2 
5.2 African cancer registries 5 
5.3 The Libyan Breast Cancer Registry 6 
5.4 LBCR Form aims 10 
5.2 Designing the Libyan Breast Cancer Registry Form 11 
5.3 Contents of LBCR 11 
5.5 Objectives 12 
5.6 Implications of the LBCR 13 
5.7 Conclusion 14 
5.8 Chapter Five References 15 
5.9 Appendix 17 
  
Chapter Six: Conclusion of thesis 1 
  
  
List of Tables  
Table 2.1 Types of Breast Cancer and Percentage 4 
Table 3.1 Description of Search Strategy 11 
Table 3.2 Assessing the Risk of Bias 13 
Table 3.3 Data Extraction Form  14 
Table 4.1 Summary of Included Studies 13 
Table 4.2 Summary of Excluded Studies 15 
Table 4.3 Assessing the Risk of Bias for Prevalence Studies 17 
Table 4.4 Risk of Bias Graph 18 
Table 4.5 Assessing Criteria for Prevalence Studies 33 
Table 4.6 PRISMA Checklist Items 34 
  
List of figures:  
Figure 2.1 Difference between DCIS and IDC 5 
Figure 2.2 Global Breast Cancer Incidence and Mortality Rates 8 
Figure 2.3 Breast Cancer Incidence and Mortality Rates by Country 9 
Figure 2.4 Number of New Cases of Breast Cancer in Africa 
Figure 2.5 WHO: Cancer Country Profile 2014 
10 
15 
Figure 3.1 PRISMA Flow Diagram 18 
Figure 4.1 PRISMA Flow Search Results  10 
Figure 4.2 Distribution of Prevalence of Breast Cancer in Africa (Map) 12 
Figure 4.3 Review of Author Judgment of Included Studies 18 
Figure 3.15 The overall Prevalence Rate of Breast Cancer in Africa 19 
Figure 4.1 The Prevalence Rate of Breast Cancer of African Females. 20 
Figure 4.2 The Prevalence Rate of Breast Cancer in the five African Region 21 
Figure 4.1 The Prevalence of Breast Cancer by Urban vs Rural Settings. 22 
Figure 4.2 The Prevalence Rate of breast Cancer in Different Study Designs 23 
Figure 4.3 The Prevalence Rate of Breast Cancer using Different Screening Methods 24 
Figure 4.4 Human Research Ethics Committee Report 36 
Figure 5.1 LBCR Form  
List of Abbreviations and Acronyms: 
• ALND = Axillary Lymph Node Dissection 
• BI-RADS = Breast Imaging Reporting and Data System 
• BMI = Body Mass Index. 
• BRCA 1/2 = Breast Cancer Gene 1 and Breast Cancer Gene 2 
• BCS = Breast Conserving Surgery 
• C50 = Breast cancer code ICD 
• CBE= Clinical Breast Examination 
• BSE = Breast Self-Examination 
• cm = Centimeter 
• CT scan = Computed Tomography 
• C = Cytology diagnosis based on microscopic examination of cells 
• DCIS = Ductal Carcinoma In Situ 
• ER = Estrogen Receptor 
• FNA= Fine Needle Aspiration 
• G = Gravida (total number of confirmed pregnancies regardless of the outcome of the 
pregnancy) 
• HRT = Hormonal Replacement Therapy 
• HER2 = Human Epidermal Growth Receptor 2 
• ICD = International Classification of Diseases  
• ILC = Invasive Lobular Carcinoma 
• IDC = Invasive Ductal Carcinoma 
• In Situ = Cancer cells not progressed through the basement membrane 
• Kg = Kilogram 
• LBCR = Libyan Breast Cancer Registry 
• LBCRF = Libyan Breast Cancer Registry Form 
• LCIS = Lobular Carcinoma In Situ 
• LN = Lymph Nodes 
• MRI = Magnetic Resonance Imaging 
• mm = millimeters 
• mmHg = millimeter mercury 
• -ve = Negative 
• P = Parity (number of pregnancies a woman has given birth to alive or lost, fetus more than 
20 more than weeks)   
• PET scan = Positron Emission Tomography 
• PR = Progesterone Receptor 
• +ve = Positive 
• RSA = Republic of South Africa 
• SLN = Sentinel Lymph Nodes 
• SLNB = Sentinel Lymph Node Biopsy 
• TNM / T=Extent of the tumor, N=Regional lymph node metastasis, M=Distant metastasis 
• U/S = Ultrasound 





THE PREVALENCE OF BREAST CANCER IN AFRICA AND ESTABLISHMENT OF THE 
LIBYAN BREAST CANCER REGISTRY 
 
Author: Muna Abdussalam Owen Abulkasim 
Supervisors: Mark E. Engel, Denver Hendricks, Leila Abdullahi, and Liesl Zühlke 
Department of Medicine, Faculty of Health Sciences, University of Cape Town 
 
Abstract: 
Breast cancer is well-known globally and remains one of the principal health concerns affecting women, 
and a rare malignancy in men. Although, there has been significant progress made in prevention strategies 
such as early detection and better treatment in most developed countries, incidence and mortality rates of 
breast cancer continued to rise. The rise is significant in Africa, a continent low in resources with a 
growing and ageing population exposed to risk factors leading to developing the disease. Although the 
incidence of breast cancer is lower in Africa than in high-income countries, mortality rates are high, 
mainly in women less than fifty years of age. 
 
Like most African countries, Libya is least prepared to cope with breast cancer and cancer in general. 
Additionally, many Libyans are adopting unhealthy lifestyles together which, together with 
environmental changes and high life expectancy, is perhaps the cause of rising cancer rates.  However, no 
systematic collection of breast cancer incidence is currently undertaken, which in turn, impacts the 
implementation of detection and treatment measures. 
 
This thesis sought to evaluate the situation of breast cancer in Africa and specifically, for Libyan patients, 







• To conduct a systematic review and literature-based meta-analysis to provide an evidence-based 
estimate of the prevalence rate of breast cancer in Africa. This systematic review provides 
epidemiological data to guide health practitioners, educators and researchers for further studies needed 
in the field of breast cancer, specific for African patients. 
 
• To design a breast cancer registry for Libyan breast cancer patients. Developing a Libyan breast cancer 
registry provides an opportunity to learn more about disease development, and the changes through the 
course of the patient's life. Secondly, we will be able to track the incidence, mortality, and survival of 
patients diagnosed with breast cancer and their distribution in Libya. Finally, the information will be 
translated into numbers to aid policymakers in measuring the extent of the problem and help researchers 





• A systematic literature search was performed to identify studies retrieved from electronic databases, 
grey literature and reference lists, with no time and language limits. We have reviewed the available 
studies addressing the prevalence rate of breast cancer for African patients living in Africa who 
developed the disease. 
 
• Secondly, the Libyan Breast Cancer Registry (LBCR) is a prospective, hospital-based registry planned 
to document clinical and imaging characteristics of patients at presentation. Through follow-up, we will 
document disease progression and treatment practices to reliably determine the incidence of all-cause 






• The overall prevalence rate of breast cancer in Africa was 0.30 [ 95% CI, 0.26 to 0.34] (22 studies, 
n=10,795). The prevalence rate of breast cancer for African females was 0.49 [95% CI, 0.38 to 0.62]. 
South African region had the highest breast cancer prevalence rate, 0.65 [95% CI, 0.24 to 1.26], while 
the lowest rates of breast cancer were from Central African regions. The use of mammography yielded 
higher rates of detection, (0.63 [95% CI, 0.46 to 0.82]), in comparison with clinical breast examination 
(0.31 [95% CI, 0.22 to 0.42]). 
 
• The proposed LBCR comprises parts I, II, AND III.  
Part I consists of demographic data and cancer information detailing personal data such as medical 
history, general examination, breast examination, methods and results of the diagnosis, and the 
treatment offered.  
Part II comprises the forms used for continuous follow-up – a new form is completed at each visit. All 
new information regarding patients’ details, new complaints, and investigation findings and any 
changes or treatment offered at the visit, are recorded in this section.  
Part III documents mortality information.  Details are recorded accompanied with a copy of the death 
certificate, and an autopsy report in case it was required.  
 
The LBCR pack includes consent forms in both English and Arabic languages. Also, it is accompanied by 
a manual of operation with given answered examples. Furthermore, the form is provided with contact 








The clinical picture of breast cancer in Africa differs from Western countries due to the high proportion of 
patients developing the disease at a younger age and seeking management care at an advanced stage. 
Currently, there exists no specific breast cancer registry designed specifically for any African patients 
living in Africa. 
 
The LBCR will provide comprehensive, contemporary data on patients with breast cancer through 
establishing a baseline figure of the current situation for future local and national comparisons. The 
LBCR includes ready and accessible information for the temporary and future use of medical elements 
and researchers in this field and will help in the development of strategies to prevent and manage breast 









INTRODUCTION TO MY THESIS: 
 
  
Chapter 1 2 
Breast cancer is defined as uncontrolled growth and division of mutated breast cells. Depending 
on the site of breast tissue and cell characteristics the cancer is classified and staged. It is the 
most diagnosed cancer of female around the world and the second leading cause of death.  
 
The primary intent of my thesis was to determine the prevalence of breast cancer in Africa by 
reviewing the available, best evidence of new and existing data of breast cancer from both 
published and non-published studies. These results are for assessing the burden of breast cancer 
on our continent by raising these figures to policy makers to overcome this enormous dilemma; 
we can also compare our results with other settings in an attempt to follow the changes over 
time.  Secondly, I also created a breast cancer registry specific for breast cancer patients in Libya 
in the attempt to easily collect information by fellow researchers and medical staff.  I focus on 
the required details related to breast cancer risk factors that are responsible in initiating the 
cancer, methods of diagnosis that are cost-effective and available, types of treatment that suite 
the state and conditions of Libyan patients. Beyond that, this registry can be used for patients 
admitted at any medical center and can provide hospitals, clinics and institutions requirements 
with costs and staff needed to accommodate patients with breast cancer. This collected 
information will be translated into numbers to aid policymakers in assessing the extent of the 
problem and help in taking action needed to minimize breast cancer burden in Libya. 
 
My literature review consists of reviewing the history of breast cancer and selecting the 
important milestones that lead to the evolution in the field of medicine regarding breast cancer. 
Furthermore, I have reviewed breast cancer epidemiology and pointed out the latest information 
Chapter 1 3 
that are available regarding this field. Lastly, I have pointed out the main reasons of the growing 
burden in Africa. 
 
For this thesis, I have registered the systematic review with PROSPRO.  I have followed the 
recommended systematic review method.  My intention is to publish the results with a title of 
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2.1 Introduction 
Breast cancer remains one of the principal health concerns that is recognized globally, and although it 
affects both sexes, breast cancer in males accounts for less than 1% of all breast cancers (1-4).  
At the moment breast cancer is the most diagnosed cancer in women, around 2.1 million new incident 
cases and 626,679 deaths in 2018 for both sexes (1,5). Breast cancer requires significant attention in the 
less developed regions of the world, particularly Africa because of the lack of infrastructure and resources 
to diagnose early and to treat individuals effectively (6,7).  
The focus of this review is to provide information about breast cancer to clinical health care workers who 
may deal with individuals with breast cancer in Africa.  
 
2.2 Breast Cancer Milestones 
The first documented breast cancer cases are believed to go back to 3000 BCE, based on medical texts 
written in Hieratic on a sheet of papyrus found in one of the ancient Egyptian tombs (8-10). In 400 BCE, 
Hippocrates described breast cancer as a humoral disease, implying a disorder in the body fluids (11), 
while Galen in 200 CE mentioned there were different types of breast tumors, some more dangerous than 
others. Galen suggested given medication such as opium, castor oil, licorice, sulfur, and salves to cure 
wounds (12,13). 
 
In the 10th century texts written by the physicians Rhazi and Ibn Sina mentioned that early diagnosis of 
cancer improved outcomes and that cancer can be managed by removing the tumor tissue in the early 
stages. However, they also stated that nothing be done in more advanced cases and that the patient is 
offered only palliative care. Rhazi correlated breast cancer with menstrual bleeding and stated the disease 
was prevalent in post-menopausal women which agrees with present knowledge (14-18). 
 
Much progress in the diagnosis and treatment of breast cancer occurred in the 19th century (19).  William 
Halsted 1882 carried out the first radical mastectomy - the surgeon removed the total breast with 
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underlying muscle and ribs in one session. This type of operation was the standard treatment for breast 
cancer.  However, this type of operation is no longer used, and other less radical options are more 
available combined with chemo-radiotherapy. Breast conserving operations were suggested in 1937, 
together with radiotherapy as part of the non-disfiguring operation in the management of breast cancer 
(20-22). By the year 1985 surgeons started routinely removing only the tumor from the breast in patients 
diagnosed with early breast cancer, followed by radiation therapy (23,24). They found this method was as 
effective as mastectomy in the management of breast cancer patients. Furthermore, in advanced breast 
cancer patients in 1988, preoperative chemotherapy was administered to shrink breast tumors and to allow 
for clear margins and perform less invasive surgeries for cancer patients (25). The first mammogram used 
to detect breast cancer was by Robert Egan, an American radiologist, reported the findings from the live 
patient, he has detected an abnormal breast lesion which was proved to be cancerous in 1962 (26,27). 
  
Regarding the link between estrogen, HER2 and BRCA in breast cancer, in 1896, George Beatson was 
the first doctor to perform ovarian removal as part of breast cancer management in women (21,28). In 
1951 it was discovered that estrogen drives the growth of breast cancer which opened a new field in the 
management plan of breast cancer. Thereafter, Elwood Jensen 1967 discovered that the presence of 
intracellular estrogen receptors benefited patients who have hormonal dependent breast cancer. 
Consequently, in 1978 Tamoxifen (an anti-estrogen drug) started being used to prevent the recurrence of 
breast cancer and also to reduce developing breast cancer in high-risk females 1998.  In 1984 the 
oncogene HER2 positive type as an aggressive breast cancer was discovered which correlates with poor 
prognosis in patients carrying this type. About ten years later the inherited genes BRCA1 and BRCA2 
were cloned, showing that mutations in these genes increased the risk of developing breast and ovarian 
cancer in women who carry these mutated genes (29,30). 
 
Better detection methods of breast cancer in early stages before any symptoms appear and new targeted 
treatment for breast cancer are currently under development. There are many different types of breast 
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cancer in patients that have different characteristics - here we will only discuss the most common types 
together with a brief review of the main approaches used in the management of these cancers. 
 
2.3 Breast cancer subtypes and stages 
Breast cancer can present as a variety of types and subtypes and can be categorized based on the level of 
spread of the disease and the tissue of origin location of the cancer cells. Table 1 below shows the 
different types of breast cancer and the percentage incidence of the various sub-types. Breast tumors are 
divided according to their invasion characteristics (31-33). 
 
 
Table 1: Types of breast cancer and percentage (32,45,46). 
 
 
In situ carcinoma 15%–30% Ductal carcinoma in situ  
Lobular carcinoma in situ  
23% 
7% 
Invasive carcinoma 70%–85% Ductal carcinoma (no special type)  
Lobular carcinoma  
Tubular/cribriform carcinoma less than  
Mucinous carcinoma  












Paget’s disease  
lee than 1% 
 
less than 1% 
 







Chapter 2          5 
2.3.1.1 Ductal carcinoma In-situ (DCIS) 
Ductal carcinoma in-situ are non-invasive mammary tumors which are often a precursor of invasive 
breast cancer. These tumors are detected by the presence of micro-calcification lesions in screened 
patients by mammography and represent approximately 25% of newly diagnosed breast cancer cases (34). 
Management of ductal carcinoma in situ includes surgery, radiation therapy, and endocrine therapy. 
Conservative breast surgery is performed in patients with microscopic foci of low-grade DCIS, however, 
even with an extensive free margin, radiotherapy, post-primary tumor resection is recommended. Sentinel 
lymph node biopsy (SLNB) is not regularly examined in patients with DCIS, but in patients who have had 
a mastectomy for the primary tumor treatment, lymph node examination is performed (35,36). Tamoxifen 
is given for five years in premenopausal women with receptor-positive tumors, while aromatase inhibitors 
are recommended for the postmenopausal period. Although endocrine therapy is given to DCIS to reduce 
recurrence rates, no data regarding the improvement of the survival rate has been recorded (37-39). 
The prognosis for patients with DCIS is excellent with full excision of the tumor, followed by adjuvant 
endocrine therapy (40). Figure 1 illustrates the different of presence of DCIS in which the tumor did not 
cross the duct, while if the tumor crossed the wall of the duct in this case is called invasive breast cancer 




Figure 1 Showing the difference between DCIS and IDC. 
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2.3.1.2 Lobular carcinoma In-situ (LCIS) 
Lobular carcinoma in-situ is noninvasive tumors that originate from the lobules of the breast. However, 
they have a high risk of developing into invasive breast cancer. The LCIS are uncommon tumors found 
when performing a breast biopsy for reasons other than breast cancer in women between the ages of 44 
and 46 years during premenopausal. However, management depends mainly on the histology of the cells. 
In pleomorphic LCIS (identified on an excision biopsy), evaluation of the surgical margins may indicate 
the need for re-excision. If an invasive carcinoma is detected, the appropriate management should be 
initiated accordingly (41-44). 
 
2.3.1.3 Paget’s disease  
Paget’s disease is a rare form of breast cancer usually less than 5% of all breast cancers that begins in the 
ducts and spreads to the skin of the nipple and areola. Patients usually present with crusts, redness, or 
oozing from the nipple. The prognosis is better when no lump is involved, and the tumor involving only 
the skin. Treatment consists of removal of the lump by breast-conserving surgery followed by radiation 
therapy, and the prognosis in this stage is excellent. In contrast, if the biopsy reveals invasive ductal 
cancer, staging is required followed by appropriate treatment (45,46). 
 
2.3.1.4 Infiltrating ductal carcinoma (IDC) 
Infiltrating ductal carcinoma is the most common type of invasive breast cancer and accounts for 50-75% 
percent of invasive breast lesions. IDC arises from the cells lining the milk duct, and the cancer cells 
gradually invade the duct wall into surrounding breast tissue and spread to other parts of the body (figure 
1). This type of breast cancer is frequently diagnosed at an early stage in regions were mass screening 
modalities are performed. They appear as numerous clusters, and pleomorphic calcifications, high-dense 
masses with calcifications, or irregular speculated border by mammogram examinations. In late-stage, 
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women present with a palpable painless fixed mass with skin changes and palpable lymph nodes. The 
treatment plan is given based on the hormone receptor status and stage (43). 
 
2.3.1.5 Infiltrating lobular carcinoma (ILC) 
Infiltrating lobular carcinoma is the second most common type of invasive breast cancers, accounting for 
about 6 % of invasive lesions. They differ from infiltrating ductal carcinoma by having a higher 
frequency of bilateral breast involvement and lesions are usually multi-centric. They usually affect older 
women and are usually estrogen receptor positive. Infiltrating lobular carcinoma tends to metastasize later 
than invasive ductal carcinomas. Moreover, the cancer cells migrate to unusual locations such as the 
peritoneum, meninges, and gastrointestinal tract (32,42,47,48). 
 
2.3.1.6 Other histologic types of breast cancer: They account for less than 5% of all invasive breast 
cancers. They include metaplastic, mucinous, tubular, medullary, adenoid cystic carcinoma, and papillary 
carcinomas (49-54). 
 
2.3.1.7 Breast sarcoma 
They are rare primary malignant tumors of the breast arising from connective tissue and accounting for 
less than 1% of primary breast cancers. Sarcomas are treated by surgical removal of the tumor, and 
radiation therapy also can be added. Because this type of cancer does not spread by the lymphatic system, 
lymph node dissection is not required (55,56). 
 
2.3.1.8 Breast lymphoma 
They usually present as a painless breast mass, a distinct subtype of Non-Hodgkin lymphoma, and treated 
with chemotherapy (57). 
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2.3.2 Breast tumor stages 
The TNM system is internationally accepted used to determine the disease stage based on tumor size (T), 
whether or not lymph nodes involved by the tumor (N) and has the cancer cells metastasized to other parts 
of the body (M). The TNM system is classified from 0 to IV and accordingly, the treatment is offered to 
patients (58). However, the management plan will consider patients’ status, tumor characteristics, HER2, 
and hormonal receptor type before the start of treatment. Stage 0 is a pre-cancer stage were tumors do not 
cross the wall of ducts or lobules, this stage is usually found in the regular screening of high-risk patients 
or as routine mammography checkups, like stage I the treatment of breast cancer patients is very effective. 
While in stages II and III of breast cancer, the tumors cells have moved beyond the basement membrane 
of ducts or lobules and the surrounded tissue with the involvement of regional lymph nodes. Stage IV, on 
the other hand, involves extension of tumor to other regions of the body, this stage is incurable, however, 
with current advances in medical technology, excellent care, and support, as well as personal motivation, 
more women are living longer (58). 
 
 
The incidence rates of breast cancer appear to have increased in previous low incidence places and 
knowledge is still limited about how geographic variations in breast cancer rates relate to specific 
etiologic factors (1,2). 
 
2.4 Global Burden 
Breast cancer is the most frequent cancer recognized in women around the world. The latest estimate by 
GLOBOCAN in 2018 has shown that there are more than 2 million new cases diagnosed with breast 
cancer (accounting for 11.6% of all new cancer cases) and unfortunately, it has caused more than a half-
million deaths (6.6% of all cancer deaths ) in the same year (1). Figure 2 below shows the difference 
between new cancer cases and number of cancer-related deaths of both sexes in 2018. 
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Figure 2 Breast cancer incidence and mortality compared to total cancer GLOBOCAN (1). 
 
The highest incidence rates of breast cancer are recorded from Australia/New Zealand, Northern, and 
Western Europe, Belgium. The presence of related risk factors and the availability of massive screening 
by mammograms may reflect on the high incidence rate of this disease in these regions (1,6,7,59).  As a 
result of increasing population size and aging of the population and an increase in exposure to cancer risk 
factors, breast cancer incidence is rising rapidly in previously lower-risk areas, such as in South America, 
Africa, and Asia (1).  
The incidence and mortality statistics of breast cancer shown in figure 3 presents a very interesting 
picture. Despite the high incidence rates of breast cancer in Australia and New Zealand (ASR, 94.2 per 
100 000); Western Europe (92.6); Northern Europe (90.1); Northern America (84.8); and Southern 
Europe (80.3), the breast cancer mortality rates for these countries (quoted as ASR per 100 000) is similar 
if not lower than other countries with much lower incidence rates of the disease (12-15) in high incidence 
countries vs 25 in Melanesia and 18 in Northern Africa). In low income countries with high incidence 
rates, women usually present in the later stage at diagnosis because screening approaches are poor 
combined with limited treatment options, resulting in lower survival rates. In terms of mortality rate 
Melanesia, Fuji had the highest record in the world see Figure 3. Mortality rates are reflected by the 
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occurrence of breast cancer as well as the availability of early detection of asymptomatic lesions and 
access to effective treatment (1,59). 
 
Figure 3 lists of the both incidence and mortality rate by countries GLOBOCAN (1). 
 
2.4.1 Breast cancer burden: Africa 
Considering the information presented in the previous section, it should be clear that despite the low 
incidence of breast cancer in most African countries, the mortality rate is similar; if not moderately higher 
than in those countries with high incidence (Figure 3). This could be that the majority of women show up 
late with advanced disease, delay in referrals to specialty centers, the high cost of drugs, cultural barriers, 
and unavailable infrastructural facilities due to unstable governments which remain a common circulating 
topic (60). 
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Figure 4 Number of new cases of breast cancer in Africa in both sexes and for females specifically 
GLOBOCAN (1). 
 
Incidence data in low and middle-income countries are calculated either from regional incidence data 
from large cities or the data is collected from neighboring countries. In Africa, only 1% of its population 
is covered with high-quality registries (61,62). That means that many people that develop cancer are not 
identified impacting on the ability to plan and supply the health service, therefore, leading to increasing 
cancer burden in Africa. Urgent activation and functioning of high-quality population-based cancer 
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registries to provide evidence-based cancer control programs are required (63). At the moment, only a 
few have been selected to submit their data of cancer incidence, because the others provide poor data 
quality. Currently, eight countries, Algeria, Egypt, Libya, Tunisia, Malawi, South Africa, Uganda, and 
Zimbabwe, report an annual incidence data. However, only four of the African countries supply mortality 
statistics from the total of 54 countries (64-67). 
 
In the year 2018, a total of 168 690 new cases was diagnosed with breast cancer representing 27.7% of 
the total cancer cases diagnosed in African women. (Figure 4). There was a moderate variation in 
estimated breast cancer incidence rates across the African regions. The estimate of age-standardized 
incidence rate per 100,000 women per year were (27.9) in Middle Africa, (29.9) Eastern Africa, (37,3) 
Western Africa, (46.2) Southern Africa, and (48.9) in Northern Africa. The rate was lowest in Middle 
Africa and highest in the Northern region of the continent, which could be explained by elevated exposure 
to risk factors, increased awareness campaigns and the commencement of screening modalities in certain 
parts of Africa (62,68-70). 
 
2.4.2 Breast cancer burden: North Africa 
The Northern African region is separated from Europe by the Mediterranean Sea in the north, and the 
Saharan desert from the rest of Sub-Saharan regions Africa. They include a total of seven countries 
(Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, and Western Sahara) with an estimate of 245,926,250 
people living in the year 2020 and share a same ethnic, cultural and linguistic identity (71). The majority 
of the population is a mixture of migratory Roman, Greek, Arabs, and Europeans distributed across the 
North region over time integrated with indigenous natives gives them unique features from the rest of 
Africa (72).  
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In terms of health care, North Africa faces several challenges, including a weak system, lack of funds, and 
poor infrastructure. However, because of a prompt rise in cancer patients in these countries, professional 
interest has grown towards the disease recently (6,7,73).  
 
Breast Cancer in North Africa 
Breast cancer is by far the most common tumor affecting women in North Africa, and estimated incidence 
from population-based registries was 29.3 per 100 000 person-years (73). However, despite its lower 
incidence in comparison with western countries, the mortality rates are higher in most of the African 
regions (1,73,74). Also, the incidence of male breast cancer in North Africa is the same as in the Western 
parts of the world. However, the relation to female breast cancer is higher, it could be explained by the 
low incidence of female breast cancer in comparison to Western countries (1,74). Furthermore, in the 
Northern African region breast cancer noted the presence of more aggressive types such as inflammatory 
breast cancer, however, the underline cause not been explanation (74).  
 
Prevalence of breast cancer risk factors in North Africa  
Hospital and laboratory-based data reported the predominant hormonal model is the major related cause 
of breast cancer which is similar to studies from developed countries (73-81). However, risk factors such 
as the age of women having a first child, the number of children a woman conceives, usage of hormonal 
drugs, and the duration of breastfeeding have changed recently and becoming more towards less 
protective from breast cancer in the developing regions (74,78-87). Women from the Arab nation are 
changing their habits using hormonal therapy in controlling the number of births, late marriage, and 
having their first child at an older age. Furthermore, more alcohol consumption, reduced in a healthy diet, 
and lack of physical exercise all could explain the increase in the incidence of breast cancer in North 
Africa. Although the behavior of women has changed, no clinical trials performed in reducing the risk of 
breast cancer in Northern African women (74-87,88). 
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Genetic studies and family history risk assessment are limited and restricted to breast cancer patients 
having a BRCA1 or BRCA2 mutation in Algeria, Tunisia, Egypt, and Morocco unlike, in Europe and the 
USA (74,78,79). While in the rest of the countries, no genetic studies were published (74,82). Trials in the 
management of breast cancer do not exist and the only available ones are part of screening or awareness 
of the disease (90,91). However, data from population-based registries from the North African countries 
are more prominent in providing updated information from its population in comparison with other 
African countries (1,74,92). In fact, most reliable high- quality data are from most of the North African 
countries have been selected to submit their data with the International Agency for Research Cancer 
(IARC) (92,93). 
 
Screening of breast cancer in Northern Africa 
The majority of African countries’ screening programs for breast cancer are not activated (93). However, 
a few promising initiatives have emerged in the last years. Although these programs included screening a 
small number of women, resulted in a noticeable increase in early mammography-detected cancers 
(74,93-102). Women aged 40 years and above were screened by mammograms in Egypt, Tunisia, and 
Morocco, however, the small number of women attended could be explained by lacking awareness 
campaign or fear of detecting cancer (90,99). On the other hand, screening women younger than 40 years 
was performed by clinical breast examination in both Egypt and Sudan indicated that breast cancer 
prevalence was high in young age groups (90,91). Despite the initiation of screening programs, there is 
still a controversy regarding the cost-effectiveness of screening in these regions (74,82,90,96,103,104).  
 
2.4.3 Breast cancer burden: Libya 
Libya is one of the largest North African countries and only 6,868,460 million citizens living in 2020. 
Although, being one of the wealthiest countries, yet the country has a serious ongoing problem. One of its 
chronic problems is mismanagement, corruption, and insufficient health care system. In the last years, the 
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Libyan health professional is facing new challenges, communicable diseases are returning, increasing 
non-communicable diseases, and war wounds have left the health system near collapse (105.106). 
 
 
                                   
Figure 5. World Health Organization - Cancer Country Profiles, 2014. 
 
Although the Libyan government offers free healthcare to its population cancer remains a low priority, 
resulting in high mortality rates in both sexes (105,107-109). In women, the most commonly diagnosed 
cancer is mammary carcinoma and its incidence is 23.8% for all female ages and has caused 14.4% 
female cancer mortality seen in figure 5 (105-110). The large number of women dying in Libya from 
breast cancer could be because of late diagnosis and unavailable management plans (74,104,111-116). 
Also, risk factors like most of the North African women Libyan women marry late and have their first 
child at a late age. Nowadays, Libyan woman has fewer children than in the past, the fertility rates was 
calculated 2.24% in the year 2018 almost half of what was in 1990 (117). Adding the duration of 
breastfeeding has changed recently, women tend not to breastfeed and use artificial milk to nourish their 
babies (118-121). Another related risk factor in developing breast cancer lack of physical exercise, it is 
estimated that 42.3% of females do not exercise and around 38 % of the Libyan females are obese, which 
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could explain the rise in the incidence of breast cancer (118-125). Furthermore, consuming an unhealthy 
diet high in fats and low in fibers, fruit, and vegetables could also increase the risk of developing the 
disease (122). This change in lifestyle together with environmental changes, hormonal changes, and high 
life expectancy is perhaps the cause of rising cancer burden in Libya (74,103,104,111). 
 
Breast cancer is more prevalent in younger age groups with a median age of 44 years, mainly during the 
pre-menopause period around ten years younger than in high-income countries and similar to most of the 
African region (78,107-110). In contrast, the median age group in males is 61 years; men pursue medical 
facilities only in an advanced stage that could explain fewer survival rates than females. The overall five-
year survival rates are 57% for men compared to females 78%, which is more than most parts of Sub-
Saharan Africa and almost similar to the rest of the North African region (74,81,88,107-112,113). 
 
 
Many reasons delay patients’ presentation for cancer diagnosis, or the start of treatment, including such as 
socioeconomic factors, unaware of a less common type of symptoms related to breast cancer which, could 
be because of lacking awareness programs (108,112-116). Another reason could explain late-stage 
presentation women having tried traditional herbal and spiritual treatments first before attending cancer 
centers (74,82,88,93). Furthermore, Libya is considered one of conservative religious countries and 
women who develop breast cancer think its destiny due to their firm belief resulting in not attending any 
check-ups or complain about their problems (74,82,88,93). Also, fear of the disease treatment will leave 
their body disfigured and feeling ashamed from family members and spouses could explain the hesitation 
in early attending medical advice (74,82,88,106,111,116). Therefore, women will only seek advice from 
medical services at a very late stage. By this time, cancer may have already metastasized to the lymph 
nodes and then spread to the other parts of the body. Thus, the option of treatment will be severely limited 
to patients at this stage, and the patient exposed to more medication toxins to the body which, enhances 
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damage to the major organs and leads to an early death. Other reasons related to health care provider–
mediated factors delayed referrals, delays in obtaining diagnostic confirmation, and availability of 
medications can prolong in the time of women starting breast cancer management (74,104,105,116,110). 
Furthermore, the health staff formed by both local and non-local members when leaving causes shortage, 
together with lacking training of local persons in all health sectors, are all part of the enormous struggles 
facing Libya today (105). 
 
 
Management of breast cancer in Libya 
Primary cancer prevention programs such as tobacco control, alcohol control, obesity prevention, and 
promotion physical activity are minimal to non-existent for non-communicable diseases (105-117,126). 
Screening and early detection are widely recognized as being a principal factor in reducing the mortality 
from breast cancer (6,7). However, awareness programs, mass screening methods are not implemented for 
breast cancer even though there are around 12 mammogram machines available and the majority of the 
laboratory can offer diagnostic tests (126). As a result, Libyan patients gave up on the collapsed system, 
patients seek medical advice from neighboring countries or even travel far too western regions (105,106). 
 
Breast cancer management is composed of a multidisciplinary team that involves different specialties: 
breast surgeon, medical oncologist, radiation oncologist, pathologist, psychologist, anesthesiologists, 
and health educator at the Oncology centers/units (125-128). The full team usually available and meet to 
discuss their patient’s management plan. However, young women in Libya do not undergo breast-
conserving surgery because of the low number of radiation therapy machines and availability of 
radiologist are only in the major cities (125-128). There are only four radiology machines and seven 
radiologists covering all cancer patients around Libya (126). Also, cancer medication is usually not 
available and costly leading to losing trust in the Libyan health system (105,106). 
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Furthermore, unfortunately, genetic work, follow-up patients, and trials regarding breast cancer in Libya 
has not been done, although the majority of research based on hospital records have shown an increase in 
the incidence of cancer patients. However, population-based registries have emerged recently, and a few 
studies became available (73,74). In 2002 the first population-based cancer registry published its data 
from Benghazi Medical Center revealed that the most common cancer among Libyan females was breast 
cancer (73,74.107).  Yet, these results were only covering 28% of the total population. (107). The most 
commonly diagnosed type of breast cancer in Libyan females was invasive ductal carcinoma and higher 
tumor grade was the predominant type of all cases (107,125,127).  One explanation for the grade 
differences may involve the more active proliferation in the premenopausal of Libyan female breast 
cancer, which is similar in young African women diagnosed with breast cancer (74,125). Most Libyan 
breast cancer women had involved regional lymph nodes at the time of surgical removal of the primary 
tumor mass and approximately more than half of Libyan patients were classified in stages III and IV 
(109,113,127,128).  
 
Cancer expected to increase across Africa, including in Libya, preventive measures associated with lifestyle 
risk factors, and implant early detection methods suitable for Libyan’s can overcome the cancer burden. 
 
The increase in breast cancer incidence around the world is probably associated with Westernized 
lifestyles, unhealthy diet, alcohol use, and sedentary lifestyle alongside changes in reproductive patterns 
causing higher risk in developing the disease (1,59-62). 
 
2.5 Risk factors of breast cancer 
The risk factors for breast cancer can be divided into two broad categories -hereditary and non-hereditary 
factors. The majority of breast cancer cases are due to non-hereditary factors, and only a small percentage 
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of breast cancer cases (5-10%) is directly due to inherited mutations in very specific genes, for example 
the BRCA gene (129,130).  
2.5.1 Nonhereditary factors 
Researchers have identified several risk factors; however, it is still not clear why some females do 
develop the disease and other not (131,132). The leading cause of breast cancer remains unexplained 
(131,132). Factors which are associated with increased risk of breast cancer include living an unhealthy 
lifestyle such as being overweight, lack of exercise, eating an unhealthy diet, and drinking alcohol (132-
136). 
The more we age, the more opportunity for genetic damage in body cells, and the body is less capable of 
repairing abnormal cells. Therefore, age is a common risk factor for developing breast cancer. However, 
African and African ancestry women develop breast cancer almost ten years younger than women from 
Western parts of the world. Even though those African women develop cancer at a younger age, they 
usually present with an aggressive disease type, which requires further investigation (137,138).  
Women that have high breast density have a higher risk of developing breast cancer — the density of 
breast tissue reflected by both the amounts of glandular and connective tissue to adipose tissue. 
Furthermore, reading mammograms to detect breast lesions is harder in high dense breast tissue than less 
dense breasts resulting in false-negative reading (139,140). 
 
 
Caucasian women are slightly more likely to develop breast cancer than African ancestry or African 
women, but mortality rates are higher in women of African descent. The high incidence in Caucasian 
women could be explained by increased accessibility to early screening by mammograms and other 
screening methods in high income setting, but probably also to an increased exposure to environmental 
risk factors. On the other hand, African women usually seek medical advice at an advanced stage of the 
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disease because of a lack of awareness and lack of population screening programs resulting in worse 
outcomes (1,7,141-143). 
 
Overweight women (having a body mass index of more than 25) have a higher risk of developing breast 
cancer compared to women with a healthy weight, especially after menopause (133,135). The relationship 
between menopause and the use of hormonal replacement therapy (HRT) and breast cancer depends on 
the duration of use and type of hormone used. HRT use has a strong association with the development of 
breast cancer and studies have shown that the incidence of breast cancer decreased in women after 
eliminating the use of HRT to ease menopausal symptoms (143-145). 
 
One of the reasons women develop breast cancer is that breast tissue ultimately develops and responds to 
high levels of estrogen hormones, which is produced in lower amounts in men (4,146). Prolonged 
exposure to hormones that are produced by the ovaries is associated with an increase in breast cancer risk, 
including early onset of menstruation, and late onset of menopause. Furthermore, exposure to high levels 
of hormones for extended periods such as conceiving a first child at a late age or never given birth are 
associated with an increased risk of developing breast cancer. Conversely, pregnancy and breastfeeding 
reduce a woman’s lifetime number of menstrual cycles, lowering the exposure to endogenous hormones, 
which are associated with a decrease in breast cancer risk. Besides, pregnancy and breastfeeding have 
direct effects on breast cells, causing them to differentiate, or mature so that they can produce milk, 
therefore, lowering the risk of developing breast cancer (147-149). 
 
Previous chest exposure to therapeutic ionizing radiation at a younger age, is associated with an increased 
risk of developing breast cancer, e.g. patients diagnosed with Hodgkin lymphoma (150,151). Survivors of 
an atomic bomb or nuclear plant accidents have also associated with an increased risk of developing 
breast cancer (152).  Exposure to diagnostic radiation in women with inherited BRCA1/2 (for example, 
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exposure to diagnostic levels of irradiation such as mammography, chest radiographs, diagnostic spine 
imaging, and computed tomography scans) have a higher risk of developing breast cancer (153).  
 
Furthermore, some factors may reduce the risk of developing breast cancer including breastfeeding and 
regular physical activity (135,154-157). A diet rich in fresh fruits, green vegetables, fish, and olive oil 
may result in lowering the risk of developing breast cancer (136,158-160). Other diets that consist of high 
concentrations of soybeans (legumes) and lignans found in a variety of fruits, vegetables, and cereal 
products are still under investigation and the evidence in preventing breast cancer is still pending (161). In 
contrast, a diet rich in amounts of fats and red meat may be increase the risk of developing breast cancer, 
although, studies are still ongoing (162). 
 
2.5.2 Hereditary risk factors 
A positive family history of more than two young relatives with breast cancer has a severe risk of 
developing breast cancer at an early age. Specific genetic mutations which predispose to breast cancer are 
suspected in females less than 50 years with a family history of breast or/and ovarian cancer. However, 
they only account for 5-10% percent of all breast cancers and include mutations in BRCA1 or BRCA2 
mismatch repair genes. BRCA mutations are seen more frequently in Ashkenazi Jews and genetically 
related communities, particularly if they are affected by breast and ovarian cancer at any age. Also, men 
diagnosed with breast cancer are suggestive of BRCA mutations (129). All patients suspected of having 
genetic predisposition should undergo a DNA test for gene sequence analysis (139).  
 
Screening of breast cancer if done at an early stage before symptoms appear will generally achieve a good 
prognosis for individuals diagnosed with breast cancer (163-165). There are many screening tests 
available to detect tumors before the development of signs and symptoms.  
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2.6 Screening for breast cancer 
Like any part of the body, the breast consists of many microscopic cells that execute the functions of 
breast tissue and also divide to form new cells to replace dead cells. However, sometimes, these cells 
undergo changes which are not detected and start to proliferate rapidly, resulting in tumor cells. Not all 
abnormal cells are malignant, only the ones that invade surrounding tissues or move to another organ. 
Therefore, these tumors require detection and treatment to prevent life-threatening problem (45,49). 
A variety of screening approaches are described below, recognizing that some will be less available than 
others depending on the medical infrastructure available in the region, and socio-economic context of the 
community.  
 
2.6.1 Breast Self-Examination (BSE) 
It is recommended that this method is performed by women every month after each menstrual cycle. 
Women are trained on how to examine the breast regularly, and symptoms and signs are explained when 
visiting a health care unit and a pamphlet explaining the method is handed to females regularly. 
Individuals will inspect their breast in front of the mirror, with regular palpation each month. This method 
is cheap and noninvasive, and the individual will be more aware of her breast and can easily detect any 
changes that appear, which should be followed by a clinical examination (see further) However, studies 
have not proved that breast self-examination can reduce mortality (166). 
 
 
2.6.2 Clinical Breast Examination (CBE) 
This method includes a full detailed history taken from the patient when visiting the health professional. 
The physician will document the patient history and will perform a full inspection and palpation of the 
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breast and axilla. This method is the oldest in screening for breast cancer. Any abnormalities detected will 
be examined in detail. The CBE has increased the screening sensitivity of young women with dense 
breasts, however, effectiveness in reducing mortality from breast cancer has not been tested through 
randomized clinical trials yet. It remains an integral part of the evaluation of women with breast 
complaints or abnormalities. In low resource settings with high risk in developing breast cancer at a 
young age, no studies have been performed to indicate the usefulness of this method. Therefore, they are 
used as part of the screening methods for breast cancer when mammography is either not available or not 
recommended for certain age groups (141,166,167). 
Likewise, clinical assessment of the axilla is not a reliable method since palpable lymph nodes do not 
indicate secondaries. For this reason, a histological examination of the removed lymph node is the most 
accurate method for assessing breast cancer spread (37,168). 
 
2.6.3 Mammography 
Mammography is a specific imaging procedure for the breast and axilla that uses a low dose of x-ray. It is 
a noninvasive test most frequently used in screening purposes, diagnosis, and follow-up of breast cancer. 
Among all the imaging modalities developed for breast cancer screening, the mammogram is an imaging 
technique that has been shown to decrease breast cancer-related deaths (169-172). The sensitivity of 
mammograms in screening is 77-95%, and the specificity is 94-97% (173). The mammography reading 
uses the Breast Imaging Reporting and Data System (BI-RADS), scored from 0-6 with each scoring 
indicating risk for further examination in suspected breast lesions (174). Nevertheless, mammography 
may miss up to 20 percent of underlying breast cancers resulting in false-negative results that increase 
morbidity and early death, whereas, false-positive readings generates unnecessary biopsies (175). 
 
Detection of cancer by mammography before symptoms and signs are present have shown a reduction of 
mortality rates by 20 % (172,173). However, mammograms are not used in pregnant or lactating women, 
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only in emergency cases. Furthermore, mammograms are not sensitive for women with breast implants or 
who have scar tissue from previous surgical procedures or trauma.  
Mammographs are not recommended before the age of 40 years or above 74 years. However, in certain 
areas around the world, women develop cancer at an earlier age, and mammography is not sensitive in 
this age group because breast tissue tends to be dense, making mammograms tests less effective. Women 
40 -49 years with a first-degree relative are advised to start screening before50 years. However, exposure 
to repeated by mammography can increase the risk in developing breast cancer, especially in high-risk 
women with the BRCA mutations who starts screening for breast cancer at an early age (39,176). 
 
2.6.4 Ultrasonography (USG) 
Ultrasound uses sound waves to generate an image, and they are more useful in differentiating whether a 
mass is solid or cystic. However, determining if the abnormality found is cancerous or calcified is not 
possible. The sonographic malignancy features include; hypo echogenicity, internal calcifications, 
shadowing, speculated mass, indistinct, or angular margins. Ultrasound is not routinely used for screening 
purposes, as it has not shown any survival benefit. However, in young suspect patients with dense breast 
tissue, this approach may detect additional breast lesions (177-179). 
 
2.6.5 Magnetic Resonance Imaging (MRI) 
MRI is a tool designed to use radio-frequency waves, a powerful magnet and computer for the diagnoses, 
staging, and development of treatment plans for diseases like breast cancer. MRI is a high-quality 
noninvasive technique for breast imaging for better sensitivity and specificity in detecting breast in high-
risk women with dense breasts (180). Additionally, in patients with unknown primary tumor, this 
approach is considered an ideal tool to search for the original tumor. They are also used in the evaluation 
of the local extension of cancer and can differentiate between surgical scars and local recurrence in 
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conservative surgery of breast cancer. Furthermore, MRI can be used to evaluate the response to 
neoadjuvant chemotherapy. Screening with MRI for breast cancer has shown a reduction in morbidity and 
mortality, due to its high sensitivity in the detection of small tumor clusters. Nevertheless, they cannot 
detect micro-calcification as effectively as mammography can (181). 
They are costly instruments and are unavailable in many centers. However, because MRI’s are so 
effective in detecting lesions, the disadvantage is that they result in more biopsies being requested and 
increase patient anxiety and cause delays in the initiation of treatment. Therefore, alternative methods, 
such as ultrasonography are recommended (181.182)  
 
2.6.6 Tomosynthesis 
Tomosynthesis is also called three-dimensional mammography or Digital breast tomosynthesis. This is an 
advanced form of breast imaging that uses low-dose x-ray and computer reconstructions to create three-
dimensional images of the breasts. They can generate accurate images and provides precise information in 
more dense tissue. Therefore, less biopsies are required and is best in the early detection of breast cancer 
lesions in women with dense breasts. Tomosynthesis has not been recommended as a screening modality 
since there is insufficient data available to measure the reduction in mortality rates.  Although women are 
exposed to more radiation with this type of tool, there is less requirement for repeated images (183,184). 
 
2.6.7 Positron Emission Tomography (PET scan) 
Because cancer cells have a higher metabolic rate than noncancerous cells, cancer cells show up as bright 
spots on PET scans which image highly metabolically active cells. Therefore, they can help identify areas 
of cancer that an MRI or CT scan may miss. They are used to monitor the patient after receiving treatment 
and detect signs of cancer recurrence. However, they are costly tools and not used as a regular modality in 
detecting breast cancer (185-187). 
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2.6.8 Computerized Axial Tomography (CT Scan/ CAT) 
CT scanning is a procedure based on x-rays that captures information from different angles combined 
with computers to create images which can be recombined to provide a high revolution view of body 
parts of interest.  They are not routinely used as a screening modality for breast cancer. Depending on the 
patient's symptoms, CT scans are requested to guide in the assessment of cancer metastasis. However, 
they have a slightly increased risk of causing cancer and are not used in pregnancy (188). 
 
All types of screening modalities are used in detecting and determining the extent of suspicious breast 
lesion; however, accurate diagnosis of cancer can only be performed by a histological examination of 
tissue biopsies. 
 
2.7 Type of Biopsies 
Most breast malignancies arise from epithelial elements, most commonly in the terminal ducal lobular 
unit. However, there are various histologic types of breast carcinomas, which differ both in microscopic 
appearance and biologic behavior. Consequently, the histological examination of biopsied breast tumor 
tissue is essential for the diagnosis and development of the subsequent treatment plan for breast cancer. 
Various biopsy modalities are routinely used to acquire sample tissue for histological analysis. 
 
2.7.1 Fine needle aspiration biopsy (FNA)  
The FNA is a procedure performed by using a thin needle to remove a small sample of cells by negative 
pressure. The cells are then examined and scored from one to five, indicating the range from benign cells 
to suspected malignant. However, bruising, bleeding, infection, and pain are the main side effects caused 
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by this procedure. Additionally, FNA has poor diagnostic results compared to core biopsy (they provide 
the type and characteristics of tumor unlike FNA), and repeated biopsies are common due to small sample 
sizes acquired. In a poor resource setting, FNA is used to diagnose breast cancer, because it’s cheaper and 




2.7.2 Core needle biopsy 
This procedure uses a broader needle to remove a larger sample of tissue under local anesthesia. Core 
needle biopsies are recommended to diagnose breast cancer. They are the best non-surgical biopsy 
procedure because they can provide enough tissue to detect cancer type, grade, and receptor 
characterization of the tumor (190). 
 
2.7.3 Image-guided biopsy 
A biopsy performed by guided imaging such as mammography, ultrasound, or MRI when the lesion is 
identified by imaging and cannot be detected by clinical examination. A stereotactic biopsy is done with 
mammography to help guide the needle under local anesthesia. A small metal clip is placed where the 
biopsy sample was collected for additional procedures if the biopsy is positively identified as breast 
cancer. The titanium clip will not interfere with future imaging tests. The procedure can be done using a 
fine needle, core biopsy, or vacuum-assisted biopsy depending on the amount of tissue being removed 
(192-194). 
 
2.7.4 Wire localization biopsy  
The wire localization biopsy is another image-guided biopsy used to sample abnormal lesions of the 
breast.  This method is used when the required tissue for examination is too small to be detected by other 
Chapter 2          28 
approaches. The radiologist inserts a wire at the site of lesion in the patient, and then the patient is shifted 
to the operation theater to remove the suspected area under general anesthesia (195). 
 
2.7.5 Surgical biopsy  
Generally, involves the surgical removal of a large amount of tissue for pathology analysis, however, this 
approach is not recommended for the diagnosis of breast cancer (196). 
 
2.7.6 Sentinel Lymph Node Biopsy (SLNB) 
The SLNB is a procedure used to provide accurate lymph node staging for breast cancer patients. In the 
negative histological reading of lymph nodes, axillary dissection not required, thus reducing the 
postoperative side effects of lymphedema and paresthesia observed in breast cancer patients.  
The SLNB procedure involves placing a dye or radioactive agents or both in the tumor bed. The dye or 
radioactivity will appear in affected lymph nodes by dissemination through the lymphatic system. The 
suspected nodes are removed for examination, and if the SLNB is negative, there is a good chance that all 
axillary lymph nodes are negative. The sensitivity of SLNB ranges from 90-95% - however, despite the 
use of this method, there is still a low recurrence rate after surgery. Meanwhile, if the result show more 
than three lymph nodes involved with cancer, axillary lymph node dissection is undertaken (ALND) 
together with the removal of the primary lesion (168,197). 
 
2.8 Treatment 
All breast cancers patients should be tested for estrogen (ER), progesterone (PR) receptor, and over-
expressions of human epidermal growth factor 2 receptors (HER2). The information of the receptor status 
of the cancer tissue is critical for both prognostic and therapeutic purposes in newly diagnosed breast 
cancer patients. There are four subgroups of breast cancer based on gene expression profile, treatment and 
prognosis are given accordingly. Luminal A breast cancer subtype is the most common subtype, and they 
carry the best prognosis of all breast cancer subtypes (ER+, PR+, and HER2- ) they benefit from 
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hormonal therapy and sometimes chemotherapy, Luminal B expressed genes (ER+, PR+, and HER2+) are 
less common and account for about 20 % of breast cancer. Luminal B carry a worse prognosis and has a 
higher recurrence rate compared with Luminal A, they benefit from chemotherapy and may also require 
hormonal or target therapy. The HER2+ subtype with (ER-, PR-, and HER2+) are likely to use both 
chemotherapy and target therapy in the patient’s management plan. While Triple-negative/ basal subtype 
(ER -, PR-, and HER2-) are associated with the worse prognosis than hormone receptor-positive and they 
usually benefit from chemotherapy (58,198-200). 
 
Once the diagnosis of breast cancer is finalized and the extent of disease and receptors status has been 
determined accurately, the treatment approach can be recommended. The exact treatment regimen will be 
determined by considering the clinical status of the patient, the age, related risk factors, and patient 
lifestyle. It is recommended that the patient be included in the discussion and be given an opportunity to 
assist in decision making, in the attempt to manage the disease. All breast cancer patients that are 
diagnosed with tumors positive for hormone receptors will receive endocrine therapy, while, triple-
negative hormone receptor breast cancer patients are offered other chemotherapeutic modalities (58,198-
200). 
 
2.8.1 Early stage breast cancer 
The early stage of breast cancer includes stage I, IIA, or a subset of stage IIB disease (T2N1) - for these 
cases, patients will undergo surgery of the primary tumor and lymph node biopsy/and or removal as a first 
treatment step. Moreover, both radiotherapy and chemotherapy may follow the surgical procedure based 
on tumor characteristics. However, patients with HER2-positive or triple-negative disease may be treated 
with neoadjuvant therapy first, followed by surgery for favorable results. The neoadjuvant therapy 
basically refers to providing treatment before the primary cancer surgery to shrink the tumor, whereas 
adjuvant therapy describes the administration of treatment after the primary surgical treatment to 
maximize the effectiveness of treatment (58). 
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 2.8.2 Advanced breast cancer 
This type of breast cancer includes locally advanced breast cancer and metastatic breast cancer types.  
They can be treated but are generally incurable, and treatment is provided to improve the patient’s quality 
of life. Patients with advanced disease have a high risk of local recurrence and develop further metastatic 
lesions.  Consequently, management must include systemic and loco-regional therapy (58).  
 
2.9 Breast cancer and pregnancy 
Although they are uncommon, they are the most common cancer in both pregnant and postpartum 
women, and they account for 2% of all breast cancer cases. Breast cancer cells have not been reported to 
transfer from the mother to the fetus, nor has termination of pregnancy been shown to have any effect on 
breast cancer outcome (201). 
The diagnosis of breast cancer in pregnant females is by core biopsy, while ultrasound, x-rays with 
abdominal shielding, and non-contrast MRI are only used to determine the extent of disease when they 
are essential (202,203). Furthermore, bone scans (required in diagnosis in advanced stages of breast 
cancer) can only be performed during the postpartum period. The hormone receptors status is usually 
negative in pregnant women diagnosed with breast cancer, and the overall survival rates are generally 
worse than non-pregnant women in all stages. The treatment guidelines are as for non-pregnant women, 
however, both mother and fetus are taken into consideration when advising the management. In the first-
trimester radical mastectomy with axillary staging is the treatment of choice, however, blue dye is 
contraindicated if SLNB is required. Technetium-99m is a safer option to detect involved lymph nodes. 
Adjuvant chemotherapy, when recommended, can be started in the second trimester, while radiation 
therapy is given only during the postpartum period.  Trastuzumab (for HER2 positive breast tumors) and 
endocrine treatment are contraindicated during pregnancy due to the high risk of congenital deformities. 
After delivery, if the mother has been advised to receive chemotherapy, she should not breastfeed, and an 
alternative feeding method should be used (58). 
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2.10 Male breast cancer 
Literature and research on screening methods, and trials for treatment options have largely focused on 
female breast cancer with less attention given to male breast cancer. This is understandable because of the 
low incidence of breast cancer in males. It is also more difficult to recruit enough participants for clinical 
trials because of the low incidence of this disease in men (3,4). 
The overall incidence of breast cancer in males is less than 1% in the United States and Europe, while in 
Africa, a study done in Tanzania, reported male breast cancer incidence to be 6% of the total breast cancer 
population (204,205). A recent meta-analysis done in Sub-Saharan Africa found that the male to female 
ratio is higher in developing countries than developed countries. This would suggest that more research is 
required on male breast cancer, particularly in developing countries. 
 
Men usually present complaining about a painless firm mass in the breast, and on clinical examination, a 
retracted nipple is commonly found by the physician.  Around 40 % of males diagnosed with breast 
cancer already have an advanced stage where tumors have spread to axillary nodes. The late presentation 
is explained by the unawareness of men in developing breast cancer and thinking the disease is restricted 
to women. However, in comparison with the age of females developing the disease, men usually develop 
breast cancer about ten years older than women do (206,207). 
As in female breast cancer, a tissue biopsy is advised with a mammogram of the breasts and ultrasound 
for the axilla to confirm the final diagnosis. Almost all invasive breast tumors affecting men are invasive 
ductal carcinoma and they account for more than 90 % of all breast cancer (206). 
 
The primary genetic mutations in males diagnosed with breast cancer is associated with BRCA 2 and 
rarely BRCA 1 when compared with females carrying the mutated gene (208). 
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In males. alcoholic consumption, radiation exposure, and increase weight are common risk factors in 
developing breast cancer similar to females. Also, drugs or diseases that stimulate excessive estrogen 
levels such as hepatic dysfunction, thyroid diseases, orchitis, testicular injury, and inherited Klinefelter 
syndrome can all increase the risk of developing breast cancer in men (209). 
 
Males diagnosed with breast cancer are treated similarly to postmenopausal females with breast cancer, 
depending on the tumor size, the number of lymph nodes involved, and hormonal receptor status. 
Modified radical mastectomy with axillary lymph node removal or lymph node biopsy is the type of 
surgical treatment performed for males. Furthermore, males diagnosed with breast cancer negative for 
hormonal receptors will benefit more from chemotherapy after removal of the primary tumor of the 
breast, while males diagnosed with hormone receptor positive breast cancer usually are given either 
Tamoxifen or undergo orchidectomy. Tamoxifen is the ideal hormonal therapy given to males (rather than 
aromatase inhibitors), due to the increased risk of developing breast cancer associated with aromatase 
inhibitors. Males usually have a poor outcome and a low survival rate compared to females diagnosed 
with the same stage of breast cancer (210-214)   
 
2.11 Prevention and conclusions 
The incidence of breast cancer is expected to grow and addressing the source of cancer is one of the 
primary tasks of public health to reduce incidence and mortality rates. Generally, there are three strategies 
to reduce the incidence and mortality associated with breast cancer (215). 
 
At the moment there is no known way to prevent breast cancer, however, preventing known related risk 
factors, early detection of the disease and proper treatment are the only available management against 
breast cancer. The primary prevention strategy requires lifestyle modification which involves the direct 
avoidance or reduction in exposure to known carcinogenic factors. This can be achieved by maintaining 
moderate alcoholic intake, maintaining a healthy body weight, and performing regular physical activity, 
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these factors are associated with reducing breast cancer risk (6,138). However, although the literature has 
many studies showings the association between specific risk factors and the risk of developing breast 
cancer these studies are not considered conclusive enough to emphatically identify critical factors which 
cause breast cancer. Much more work is required in this area so that we can impact on the incidence of 
breast cancer like was done for lung cancer and smoking. Females at an increased risk because of the 
presence of an inherited mutated BRCA gene for instance could take medication like tamoxifen or 
perform surgical removal of breasts to reduce their risk. 
 
Secondary prevention strategies help to reduce the mortality of breast cancer through screening modalities 
to detect early lesions before symptoms and signs appear. However, regular effective screening is a reality 
only in economically strong countries and are nearly completely absent in poor countries such as most of 
Africa. Therefore, disagreement about the age of commencement and the frequency of mammography 
screening led to the diversity of screening approaches in middle and low-income countries, because of the 
lack of resources (216). 
 
The tertiary prevention strategy is in the form of cancer management plans such as cancer therapy and 
palliative care to improve the quality of life and survivorship; however, in low resource settings, 
availability may be limited or incomplete increasing both morbidity and mortality (61,217). 
 
In conclusion, it would appear that based on the available information, the early detection and treatment 
of breast cancer is still is the best approach to reduce the mortality associated with this disease. Preventing 
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3.1 Background 
The number of diagnosed females with breast cancer has grown over recent decades due to widespread 
screening and advances in clinical procedures in the methods of diagnosis (1) (2) (3) (4) (5). There are 
around 2.1 million women globally (2018), and it is estimated that it will reach up to 3.2 million new 
cases by the year 2050 (6) (7) (8). Across the world, the highest incidence rate of breast cancer is among 
developed countries. However, mortality rates of breast cancer have dropped in comparison with less 
developed countries  (6), (9) (10) (11) (12). This decrease in mortality rates of breast cancer in developed 
countries is due to early diagnoses and proper management of patient, which prolongate the survival rates, 
90% of females with breast cancer survive for more than five years after treatment in the United States 
and Canada, while in the Gambia, only 12% do survive (13) (14). 
 
The African continent has the second largest number of people in the world, and it is expected to grow up 
to 4.1 billion by the year 2100. This fast growth in population and rising of life expectancy in Africa, lead 
to increased incidence of diseases. Among these diseases, breast cancer incidence in females has 
increased in most of the African countries. The latest data in 2012 has reported there where about 133,900 
women newly diagnosed with breast cancer within 26 countries in Africa (15) (16). Females of white 
ethnicity living in South Africa have the highest incidence of breast cancer, probably due to adaptation of 
western lifestyle, increase in smoking and increase the use of hormonal birth control for family planning  
(9) (17) (18). Also, some studies have included male breast cancer in Africa, and they have reported that 
male-to-female ratio of breast cancer in the African countries is slightly higher than reported from 
western parts of the world (19). 
 
Difficulties that are increasing cancer burden in Africa, cancer registry and high-quality data only covers 
1% of the African population residing in Africa, and most of the available data are based on hospital 
records, missing patients that are unable to reach medical advice (20, 21) (22) (23). Therefore, the actual 
figures of breast cancer incidence, prevalence, and mortality rates cannot be measured accurately, leading 
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to unsuccessful management plans. Another problem facing the health officials is late detection of cancer, 
patients in most of the African countries first seek traditional herbal medication or consider cancer a 
destiny due to their firm religious belief (24) (25) (26) (27) (28). As a result, women will only seek 
medical advice from western medical services at a very late stage. By this stage, cancer may have already 
metastasized to the lymph nodes and then spread to the other parts of the body, severely limiting the 
treatment options available to patients at this stage (23) (29) (30) (31) (32). Also, war and political 
changes have caused instability in many parts of Africa, which has affected the health sector and 
prevented its progress. We are performing this systematic review to determine the prevalence of breast 
cancer in Africa and with the view that it will assist health professionals and policymakers in 
programming priorities for early detection, treatment and provide evidence for research in attempting to 
decrease the breast cancer burden in Africa.	
 
 Why is it important to do this review? 
This systematic review will provide epidemiological data that can be used to guide health practitioners 
and educators for further studies needed in the field of breast cancer. 
 
3.2 Objective 
To conduct a systematic review of studies assessing the prevalence of breast cancer on the African 
continent. 
 
3.3 Review question 
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3.4 Selection studies 
3.4.1 Inclusion criteria 
1. Studies describing the prevalence of breast cancer among male or female’s participant, residing in 
Africa and diagnosed with breast cancer by histopathology reports. 
2. We will include observational, population-based studies, trails, and cross-sectional studies of breast 
cancer. 
3.4.2 Exclusion criteria 
1. Studies with benign breast disease. 
2. Studies which are not including African countries. 
3. Studies which are including African population living other than African countries. 
4. Studies that do not include histopathology diagnosis of breast cancer. 
5. Narrative reviews, opinion pieces, and letters. 
6. Studies based on hospital records without population screening. 
 
3.5 Outcomes 
Our outcome of interest includes the following 
 
 3.5.1 Primary outcomes 
• Prevalence of breast cancer in both sexes 
• Prevalence of breast cancer in females. 
 
3.5.2 Secondary outcomes 
• Prevalence of breast cancer by regions 
• Prevalence of breast cancer in different settings. 
• Study designs used in detecting breast cancer prevalence. 
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• Prevalence of breast cancer by different methods of diagnosis. 
 
3.6 Search strategy for identification of relevant studies 
Both published articles and unpublished papers will be considered with no time and language restrictions. 
The studies to be included will be selected using predefined search terms adapted for the database that 
will be used. Diagnosis of breast cancer will be based on histopathology reports. The search will be 
performed to all articles published in English or other languages related to the country original language. 
 
Bibliographic databases 
A. An expert librarian will help in the research strategy by checking the design that has been placed to 
ensure that there will be no missing articles or papers relevant to the title. We will start by checking 
the keywords that are used in the title and possibility of other synonymies.  
B. An exhaustive search strategy with relevant subheadings will be used to identify all studies on the 
prevalence of breast cancer in Africa, in various databases like PUBMED/ MEDLINE, Cochrane 
database, EBSCO host (CINHAL/African Wide information), Web of Science, African index medics, 
Lilacs, and Scopus. Besides, we will conduct a manual search through the internet in google scholar, 
ProQuest and search World CAT for thesis, dissertation and conferences proceedings for any missing 
literature that was not published. The search terms will include both sexes male and females, 
prevalence and epidemiology, and we will specify the search to humans with the exception of 
children. The African search will include all countries of the African continent separately, and a 
further search by truncated names, e.g. (North Africa, Sub-Saharan region). We will consider the 
political name changes that occurred to countries over time, e.g. (Jamahiriya to Libya) and also the 
names of countries in different languages according to the country original language. We will search 
for studies from the references of articles that have been filtered for inclusion in the various database. 
C. A clear, detailed search strategy is explained in appendix 1. 
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3.7 Selecting studies for inclusion 
Two review authors will screen the titles and/or abstract of the studies that have been extracted using the 
search strategy independently. During the screening, the studies will be marked as either included, 
excluded, or pending. In the studies that are marked pending, a discussion will be undertaken to agree 
either include or exclude studies with a detailed explanation of reasons. For the studies that meet the 
inclusion criteria, a full text of these studies will be reviewed, and their details completed onto a data 
extraction form that will be designed by our team. The two reviewers should agree to the final number of 
studies. The search steps will be documented on PRISMA flow chart. (Figure 1) 
 
3.8 Quality appraisal of included studies 
The guidelines for evaluating prevalence studies by Hoy et al., modified by Werfalli and colleagues (33), 
will be used to measure the quality of studies through an external and internal validity as shown in (Table 
1). The quantitative scoring system to the Risk of Bias criteria allocates four points of external validity 
and six points of internal validity. The scoring system tool categories high-risk studies as those with an 
overall score of 0-5 points, moderate risk as 6-8 and low risk >8 points. Two review authors will 
independently assess the risk of bias for each included study. In case of any disagreement, a third 
reviewer author will be consulted to resolve the disagreement. 
 
3.9 Data extraction and management 
Two review authors will independently extract data from the studies that are selected according to the 
criteria of inclusion and complete them in a data extraction form which is designed by the study team 
members. The data extraction form will first be piloted independently by two study team members using 
the same studies to assess comprehension. In case of discrepancies with data extraction, a third study team 
member will be consulted, and the difference resolved by consensus. The data extraction form is shown in 
(Table 2). 
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3.10 Data synthesis including assessment of heterogeneity 
Data shall be presented in text, tables and figures documenting the numerators and denominators of breast 
cancer to be used for calculating prevalence. Data from outcomes of two or more similar studies will be 
pooled for analysis using a random-effects model where significant clinical and methodological 
heterogeneity exists between studies. Pooled statistics for breast cancer prevalence will be expressed as 
prevalence ratios with 95% confidence intervals (CI). Where a meta-analysis cannot be carried out due to 
significant heterogeneity, results will be presented in a narrative form. 
 
Data will be pooled to assess heterogeneity, assessed firstly by visually inspecting the forest plots. 
Secondly, the Chi-squared test for homogeneity with a significance level set at 10% will be used. Finally, 
the I2 statistic will be used to quantify any statistically significant heterogeneity between study results and 
rated as ‘low ’for ≤ 49% and ‘moderate ’for 50-74% and ‘high ’for ≥ 75% (34). 
Efforts will be made to retrieve missing data by contacting the corresponding authors for the included 
studies. Where this is not possible, values will be imputed for primary outcomes in order to enable an 
intention-to-treat analysis. The other outcomes will be analyzed with only available data. 
Subgroup analysis will be carried out based on the study design, study setting and demographic 
characteristics of participants including race, sex, the region of study, the facility available and the year of 
diagnoses if possible. Sensitivity analysis will be carried out where imputations were done for the primary 
outcomes and also to determine if the study designs, study period or publication type have an impact on 
the results of the meta-analysis.  
 
3.11 Assessment of reporting biases 
Asymmetry funnel plot will be constructed to assess the risk of publication bias per type of intervention if 
each intervention type included in the meta-analysis has over ten studies of varying sizes. Then it will be 
examined for asymmetry visually and statistically using the Egger test and Harbord test (35). 
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3.12 Reporting of this review 
According to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
Statement (36), the systematic review will be reported. A reporting guideline for systematic reviews of 
healthcare intervention and will include a PRISMA checklist.  
 
3.13 Ethics and Dissemination 
This systematic review will endeavour to fill in the gap of information on the prevalence of breast cancer 
on the African Continent. The study will provide prolegomena of evidence to future researches and will 
be disseminated by peer-review publication and conference presentations. Ethics approval is not required 
for this systematic review, patient’s data will not be used, nor there will be any intervention with patients.  
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Appendix 1: A descriptive detail of the search strategy. 
MeSH in PUBMED/MEDLINE 
Name used Distributive electronic search terms.  
Participants   “female” [MeSH] OR “Female” [All field] OR “Male” [MeSH] OR “Male” [All field] 
OR”Not Children”[MeSH] OR”[All field]. 
AND  
Breast cancer “breast neoplasms”[MeSH Terms] OR “breast neoplasm” [All field]  OR “ human 
mammary carcinoma”[MeSH terms] OR”human mammary carcinoma”[All fields] OR 
“mammary neoplasms”[MeSH terms] OR “mammary neoplasms”[All fields] OR “ductal 
carcinoma”[MeSH] OR”ductal carcinoma”[All fields] OR “lobular carcinoma”[MeSH 
Terms] OR “lobular carcinoma”[All fields] OR “Infiltrating ductal carcinoma” [MeSH 
terms] OR”infiltrating ductal carcinoma”[All fields]  
AND  
Prevalence “epidemiology” [subheading] OR” epidemiology” [All fields] OR “prevalence” [MeSH] 
OR “prevalence” [All fields] 
AND  
Africa  “lower income”[MeSH terms] OR”lower income”[All fields] OR “middle income”[MeSH 
terms] OR”middle income[All fields] OR “Africa”[Mesh terms] OR”Africa”[Al fields] OR 
“Nigeria”[tw]OR”Ethiopia”[tw]OR”Egypt”[tw]OR”Democratic Republic of 











Tome and Principe”[tw] OR”Seychelles”[tw] OR”Saint Helena AscenSion and Tristan 
da Cunha”[tw]OR”North Africa”[tw] OR”Sub Saharan Africa”[tw] OR”East Africa”[tw] 
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Scopus/Africa and CINHAL/Web of science/Lilacs 
 
(Breast Neoplasms) OR (male breast neoplasms) OR (breast malignancy) OR (breast tumour) OR (breast 
tumour) OR (human mammary carcinoma) OR (mammary neoplasms) OR (breast carcinoma) 
OR (lobular carcinoma) OR (infiltrating ductal carcinoma) OR (ductal carcinoma) 
 AND  
 




Africa OR African OR (west Africa) OR (east Africa) OR (east Africa) OR (Sub Saharan Africa) OR 
(North Africa) OR (African Arab) OR Algeria OR Angola OR Benin OR Botswana OR (Burkina 
Faso) OR Burundi OR Cameroon OR (Canary Islands) OR (Cape Verde) OR (Central African 
Republic) OR Chad OR Comoros OR Congo OR Democratic Republic of Congo OR Djibouti 
OR Egypt OR Eritrea OR Ethiopia OR Gabon OR Gambia OR Ghana OR Guinea OR (Ivory 
Coast) OR (Cote d'Ivoire) OR Jamahiriya OR Kenya OR Lesotho OR Liberia OR Libya OR 
Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Mayotte OR Morocco OR 
Mozambique OR Namibia OR Niger OR Nigeria OR Principe OR Reunion OR Rwanda OR (Sao 
Tome) OR Senegal OR Seychelles OR (Sierra Leone) OR Somalia OR (St Helena) OR Sudan OR 
Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR (Western Sahara) OR Zaire OR 
Zambia OR Zimbabwe. 
 
 Manuel search for articles, conferences, Books and thesis by World CAT and ProQuest 
thesis and dissertations. 
 
 Google Scholar search.    
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Appendix 2: Table 1 
  
 
External validity  
1. Was the study’s target population a close representation of the national population in relation to 
relevant variables? (1 point) 
2. Was the sampling frame a true or close representation of the target population? (1 point) 
3. Was some form of random selection used to select the sample, OR was a census undertaken? (1 point)  
4. Was the likelihood of nonresponse bias minimal? (1 point)  
Total points (4 points)  
Internal validity  
1. Were data collected directly from the subjects (as opposed to a proxy)? (1 point) 
2. Was an acceptable case definition used in the study? (1 point) 
3. Was the study instrument that measured the parameter of interest shown to have validity and 
reliability? (1 point) 
4. Was the same mode of data collection used for all subjects? (1 point) 
5. Was the length of the shortest prevalence period for the parameter of interest appropriate? (1 point)  
6. Were the numerator(s) and denominator(s) for the parameter of interest appropriate? (1 point)  
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Appendix 3 Table 2: Systematic review data extraction form 
 
A. Source: 
Reviewer title Prevalence of breast cancer in the African continent. 
Study ID Muna Abulkasim 
Name of person extracting data  
Initial of person extracting data  
Date of filling the form ——/——/20—— 




Reference citation  
Published Yes, No        Name of Journal:                  




Publication type Full-text Abstract    Book   Conference   Thesis    Others: 
Country of origin  
Language of study Eng   Fre   Ger    Arabic     Africans       Other 
 
Translation:    Yes    No 
Year of publication ——/——/—— 
Reference of potentially eligible 
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B.Study eligibility: 
Study design Cross-section   Population-based registry    Others    
Study period  
Data source Hospital: 1ry  2ry   3ry    Private     Survey      Others 
Population study Total    Specific group        Others 
Setting rural   urban   not mentioned 
Prevalence Yes       No         Unclear 
Study  Included           Excluded        Pending 
Excluded reason  





Hoy guide Q Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 
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C. Study characteristic: 
Type of screening BSE     CE      U/S      Mammo     Histopathology  Other 
The common type of breast cancer  
The common site of breast cancer  
Age group M             / Mean           F            /Mean    Both      /Mean 
Stage of disease Early       Late       Unclear     I   II  III  IV    
ER / PR / HER 2  Luminal:   A   B       TN/B-L        N-L            Her2-enriched 
Genetic studies available Yes       No     Not mentioned 
Treatment  Surgical           Chemotherapy         Radiotherapy        Hormonal 
Follow up Yes       No     Not mentioned 
5-year survival Yes       No     Not mentioned 
Gender M     / Denominator 
F      / Denominator 
Both / Denominator 
Ethnicity  



















Measure of the prevalence Crude measure                    Adjust measure  
 If adjusted what factors were 














Author was contacted Yes        No 









   
  



























From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews 




Full-text articles assessed 
for eligibility 
(n =   ) 
Full-text articles excluded, 
with reasons 
(n =   ) 
Studies included in 
systematic review 
(n =   ) 
Records excluded 
(n =   ) 
Records screened 
(n =   ) 
Records after duplicates removed 
(n =   ) 
Additional records identified 
through other sources 
























Records identified through 
database searching 
(n =   ) 
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Abstract 
Introduction 
Breast cancer is well-known globally and remains one of the principal health concerns affecting 
women, and a rare malignancy in men. Although, there has been significant progress made in 
prevention strategies such as early detection and better treatment in most developed countries, 
incidence and mortality rates of breast cancer continued to rise. The rise is significant in Africa, a 
continent low in resources with a growing and ageing population exposed to risk factors leading to 
developing the disease. We have percolated this systematic review and meta-analysis as a reliable 
form of medical evidence to measure the prevalence of breast cancer in Africa.  
 
Methods  
We searched, using an African search filter with no time limits, electronic databases, grey literature 
and reference lists for eligible primary studies meeting pre-specified criteria. Two authors 
independently screened the search outputs, selected studies, and extracted data; resolving 
discrepancies by consensus and discussion. Using Stata software, we applied the random-effects 
meta-analysis model to aggregate prevalence estimates with 95% CI incorporating the Freeman-
Tukey transformation to account for between-study variability. 
 
Results 
The overall prevalence rate of breast cancer in Africa was 0.30 [ 95% CI, 0.26 to 0.34] (22 studies, 
n=10,795). The prevalence rate of breast cancer for African females was 0.49 [95% CI, 0.38 to 0.62]. 
South African region had the highest breast cancer prevalence rate, 0.65 [95% CI, 0.24 to 1.26], while 
the lowest rates of breast cancer were from Central African regions. The use of mammography 
yielded higher rates of detection, (0.63 [95% CI, 0.46 to 0.82]), in comparison with clinical breast 
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Conclusions  
The clinical picture of breast cancer in Africa differs from Western countries due to the high 
proportion of patients developing the disease at a younger age and seeking management care at an 
advanced stage.  Currently, there exists no specific breast cancer registry designed specifically for any 
African patients living in Africa and thus, prevalence studies of breast cancer from African countries 
are limited.  The results emphasize the need for resources to further research the causes of breast 
cancer and affordable alternative methods for early diagnosis, especially given the low resource 
setting. The study contributes evidence to the current situation on breast cancer in Africa and stresses 
the need for health professionals and policymakers in programming to priorities early detection, 
treatment and ominous need for evidence to decrease the breast cancer burden in Africa. 
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4.1 Introduction 
Mammary cancers are the most frequently detected malignancies in women and are considered one of 
the leading causes of death around the world (1) (2) (3). According to the global geographical 
distribution, breast cancer incidence is highest among Australia/New Zealand, Northern America, and 
North-Western regions of Europe (1, 3). This high incidence is reflected by the high prevalence of 
risk factors and genetic mutation in specific ethnic groups, regardless of the high incidence, the 
mortality rates from this disease have declined on account of advances in early detecting plans and 
availability of treatment option for controlling the cancer growth among these regions resulting in 
more women surviving with the disease (1) (4).  
 
In Africa, women develop the disease at a younger age and present at a late stage in comparison with 
western countries (4) (5) (6) (7). Due to a lack of awareness, late-stage presentation, lack of early 
detection programs, limitation of standard pathological services and inaccessible treatment 
opportunities, mortality rates of breast cancer have increased (7) (8) (9) (10). Therefore, only a 
minority of women diagnosed with early breast cancer in most African countries. Since increasing 
and ageing of the population on the African continent, change of environment, adapting of new 
lifestyles, and exposure to cancer risk factors, more and more women will develop breast cancer, thus 
causing a rise in the cancer burden (11) (12) (13) (14) (15) (16) (17)(18). 
 
The definition of prevalence rate is the total number of newly diagnosed people and people who are 
alive with the same disease at a specific time. Prevalence studies are useful in informing health care 
professionals of disease geographical distribution and in monitoring trends over time and provide 
information for further etiological studies and investigate the causes of disease. 
 
4.2 Aim 
We have percolated this systematic review as a reliable form of medical evidence to measure the 
prevalence of breast cancer in Africa, with the intention to document the status of the current 
situation. This study is aimed at assisting health professionals, government, and policymakers to 
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inform, plan the selected interventions and to deliver a better health care service for the general 
population of Africa. 
 
4.3 Methods 
This systematic review protocol has been published in the PROSPERO International Prospective 
Register of Systematic Review (http://www.crd.york.ac.uk/PROSPERO), with a registration number 
CRD42017080780 and was checked according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis Protocols (PRISMA-P) 2015 Statement (19) (20)  in (Appendix1). The 
full detail of the protocol is available in Chapter Three. 
  
4.3.1 Criteria for included studies 
Types of studies 
Cross-sectional, observational, randomized control trails, and population-based studies were selected 
and included in this systematic review. Studies with no pathological evidence of diagnosis of breast 
cancer, studies based on only hospital or laboratory/Pathology records without population screening 
were excluded (studies with no denominator).  
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4.3.2 Types of Participants 
Studies described the prevalence of breast cancer among male or female participants, residing in 
Africa and diagnosed with breast cancer by histopathology tests. 
  
4.3.3 Types of outcomes 
Primary outcomes: 
• Prevalence of breast cancer in both sexes 
• Prevalence of breast cancer in females. 
 
Secondary outcomes: 
• Prevalence of breast cancer by regions 
• Prevalence of breast cancer in different settings. 
• Study designs used in detecting breast cancer prevalence. 
• Prevalence of breast cancer by different methods of diagnosis. 
 
 
4.3.4 Search strategy for identification of relevant studies 
A comprehensive search was conducted from both published and non-published studies, with no 
language restriction and time limitation by both authors [MA, LA]. An expert librarian helped with 
the research strategy. Subheadings were used to identify all studies on the prevalence of breast cancer 
in Africa of various databases like PUBMED/ MEDLINE, Cochrane database, EBSCO host 
(CINHAL/African Wide information), Web of Science, African index medics, Lilacs, and Scopus. 
Also, we conducted a manual search using google scholar, ProQuest, and search World CAT for 
theses, dissertations, and conference proceedings for any literature that was not published.  
Search terms included both male or female, prevalence and epidemiology and had limited the search 
to humans, except for children. The African search included all countries on the African continent 
separately, and a further search performed by truncated names, e.g. (North Africa, Sub-Saharan 
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region). We considered the political name changes that occurred to countries over time, e.g. 
(Jamahiriya to Libya) and also the names of countries in different languages according to the 
country’s original language.  Finally, we searched studies from the references of articles that have 
filtered from the pooled studies in the various databases.  A descriptive detailed search strategy is 
explained in Appendix 1 - chapter 3. 
 
  
4.3.5 Data extraction and management 
The two authors, MA, and LA independently extracted data from the studies selected according to the 
inclusion criteria onto a data extraction form designed by the study team members.  
The data extraction form was first piloted independently by the team members MA and LA, together 
with author ME as the third author reviewing the data extraction form. The modified data extraction 
form is shown in Appendix 3 - chapter 3. 
  
4.3.6 Selecting studies for inclusion 
MA and LA screened the titles and abstracts of all the identified records from both the database 
searches, and the additional manual searches pooled into EndNote with automatic removal of 
duplicates. The screened studies were marked as either included, excluded, or pending by the two 
authors separately MA and LA. In the studies that are marked pending, a discussion undertook to 
agree either to include or exclude the studies with a detailed explanation of reasons. A third reviewer 
ME was consulted with the discussion and revision of the inclusion criteria until an agreement 
reached to the final number of studies. We used a flow diagram from PRISMA guidelines for this 
systematic review for all studies selected and summarized in Appendix 4 – chapter 3. 
 
  
4.3.7 Quality appraisal of included studies 
We evaluated quality assessment using the tool by Hoy et al. modified by Werfalli and colleagues 
(21). The scoring system categorises studies as high-risk (overall score of 0-5 points), moderate risk 
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(6-8 points), and low risk (>8 points).  The Quality assessment criteria for prevalent studies with 
scoring (Red -high risk, Yellow -medium risk, and Green low risk can be found in appendix 5. Studies 
using randomized trial designs were assessed using the Cochrane tool for the risk of bias (appendix 
6). 
 
4.3.8 Data synthesis including assessment of heterogeneity 
Data were analysed using Stata statistical software.  Firstly, prevalence estimates were recalculated 
using the given numerator and denominator for each study (Table 5 explains all the collected 
information from each study in the result section). Then, the overall prevalence from the eligible 
studies of the systematic review was calculated including 95% confidence intervals (CI). Secondly, 
we estimated the prevalence for each subgroup and analysed regions within the African continent and 
settings. We also stratified the prevalence results according to the female gender, type of screening 
methods conducted in the selected studies outcomes, and study design. 
 
In addition, heterogeneity between the studies were assessed by using the chi-square test and I2 
statistic; we regarded heterogeneity as substantial when I2 was more than 50% (20).  
Lastly, we assessed all the included studies by using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) approach for the certainty of evidence. Findings of the 
assessment across studies using the GRADE are judged as having high, moderate, low or very low 
levels of certainty. Certainty lowers each time there is a serious concern with the risk of bias, 
inconsistency, indirectness, imprecision, and publication bias. High certainty evidence implies that 
further research is very unlikely to change our confidence in the estimate of effect. Moderate certainty 
of evidence means that further research is likely to have an important impact on confidence in the 
estimate of effect and may change the estimate. When the evidence is considered of low certainty if 
further research is very likely to have an important impact on our confidence in the estimate of effect 
and is likely to change the estimate. While very low certainty if we have very little confidence in the 
effect estimate (22) (23) (24). 
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4.4 Results  
4.4.1 Description of the studies 
Our results following a comprehensive search strategy yielded 10,067 records that were pooled 
together into Endnote reference management software. A total of 1067 studies were identified as 
possibly meeting with our inclusion criteria, after screening titles and removal of duplicates 
electronically. Thirty-four studies we eventually determined needing review of full text, resulting in 
the removal of 12 articles; the excluded studies reasons shown in table 2. Thus, 22 studies are 
included in the quantitative systematic review and meta-analysis. Steps of the search results are 
documented in the flow diagram from the PRISMA chart (figure1). 
 
Study description: Details of the included studies gathered measuring the prevalence of breast cancer 
are shown in Table 1. The main points include author and the year of publication, the study period, 
study design, the type of participant, the country of origin, type of setting, the method used in the 
diagnosis of prevalence for each study. 
Language Restriction: Out of the twenty-two articles, 19 were in English leaving with three French 
studies requiring translation into English (25) (26) (27).  
The English language studies are: (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) 
(42) (43) (44) (45) (46) 
Study design: Most of the studies included are screening in nature (cross-sectional studies) and 
retrospective. Only two studies provided prevalence report from trail studies (28) (29). 
Participant characteristics: 19 studies have included only female participants in the screening and 


























Figure 1 PRISMA 2009 Flow Diagram (search results).  
Records screened 
(n = 1067) 
Records after duplicates removed 
(n =8997) 
Additional records identified 
through other sources 
(n =35) 
Records identified through database 
searching 
(n = 10032) 
Full-text articles assessed 
for eligibility 
(n =34) Full-text articles excluded, 
with reasons (n=12) 
 
No denominator (n=3) 
Prevalence by age(n=2) 
Prevalence by region (n=1) 
No prevalence rate (n=6) 
 Studies included in 
systematic review 
(n =22) 
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Age characteristics: The youngest age screened for breast cancer started from 18 years, while the 
oldest age groups, including women of 90 years. A total of 9 studies have calculated the mean age of 
participants, and the rest gave the range of screening except for one study, which has not mentioned 
the age group (29). 
Study origin: All the studies conducted in Africa met our inclusion criteria (Figure 2). The majority 
of the studies were from North Africa {Three studies from Morocco  (30) (31) (32)   Two studies 
from Sudan(33) (34), Three studies from Egypt (28) (35) (36)  and Three studies from Tunisia (25) 
(26) (27) . West Africa represented by five studies {two from Nigeria (37) (38), one study from 
Cameroon (39)  and two from Ghana (40) (41). A study each from Tanzania (29), Kenya (42) 
conducted from East Africa. Central Africa region had included only one study from DR Congo (43). 
The remaining three studies were from RSA (44) (45)and Zambia (46). 
  
Only two studies have not mentioned their setting origin. Out of the 20 studies, there were seven 
performed in rural parts of the continent.  
Study period: The earliest study was conducted in 1999 to calculate prevalence results (40) and our 
search ended by the end of the year 2018. The most prolonged study period calculated the prevalence 
for ten years (44). Both studies (28) (35) have not mentioned any information regarding the start and 
end of the study period.  
Study samples: The most significant study sample covered three million of its population (30), while 
the smallest sample included 1094 recruited female (42). 
Prevalence count: Result of the prevalence of breast cancer was available in most of the studies in 
our review, However, when the final figure was not available calculation was performed since both 
the nominator and denominator are present in all the included studies as shown in Table 1 below. 
 
 







Figure 2: Distribution of Prevalence of breast cancer in the African countries.
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Table 1: Summary of the Included studies  
Author country Setting study period study 
design 
gender common type age specific Method used in 
diagnosis 
n (m) n(f) N 
Abuidris,2013  Sudan rural 2010-12 CS-pilot F - >18 CBE, MMG, U/S 17 10 309 
Agbo,2014  Nigeria urban 2007-11 Retro F Invasive ductal3,4 48,2 - 288 2 781 416 
Agyei-Frempong, 
2008  
Ghana u/r 1999-2002 CS F - 47.77, - 102 15 221 
Apffelstaedt,2014  RSA - 2011-12 CS/pilot F - 40-70 MMG 10 2 712 
Apffelstaedt,2014  RSA - 203-2012 CS F Invasive >40 MMG 43 3 774 
Basu, 2018  Morocco u/r 2015-16 SC F - 40-60,49.5 CBE,  1,048/1,238 1,000,000/1,600,000 
Boulos,2005  Egypt urban - Trail F - 35-64 CBE, MMG, U/S 20 4 116 
Chraka, 2018  Morocco rural 2012-14 Retro F - 45-69 CBE,  224 184 951 
Denewer,2010  Egypt rural 2-year study CS/pilot F G 2,3 46 CBE, MMG, U/S 18 5 900 
El-Fakir, 2015  Morocco urban 2009-11 Retro/SC F - 45-70 CBE, MMG, U/S 4 2 350 
Frikha,2013  Tunis urban 2004-10 CS/pilot F - >45-86,51.5 MMG 56 10 000 
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Kribi,2003  Tunis urban 1995-97  F Invasive 40-70 MMG 10 2 200 
Mvila,2014  Congo urban 2010-12 CS F Invasive >18 CBE, MMG, U/S 100 4 315 
Naku,2016  Ghana rural 2007-8 CS F Invasive ductal 25-54 CBE, MMG, U/S 24 3 000 
Ngoma,2014  Tanzania rural 2009-11 TRAIL F/M - - CBE, biopsy 42 10 979 
Ozolio,2014  Nigeria rural 2009-10 Pros/CS F - >35,12-90 MMG 29 2 095 
Pinder,2018  Zambia rural 2008 CS F - 35,9 CBE, U/S 6 1 129 
Saeed, 2016  Sudan u/r 2009-13 CS/Pop F/M - 36-45 - F=5,500/M=
250 
36 163 778 
Sando,2018  Cameroon u/r 2008-15 CS F/M DuctalG2,3 47,9 - M=15/F=14
70 
22 179 707 
 Salm,2008  Egypt urban 2007-2008 CS/pilot F Invasive ductal >45 MMG 159 20 098 
Sayed,2016  Kenya u/r 2015 CS/pilot F Invasive m=36.5 CBE, MMG, U/S 15 1 094 
Zaanouni,2009  Tunis urban 2004-06 CS/pilot  F Invasive 40-
69/m=48.9 
MMG 27 5 325 
 
CS=cross-sectional studies, MMG =mammograms, U/S = ultrasound test, u/r = both urban and rural, CBE = clinical breast examination, Pop =population-based screening. 
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Table 2 Excluded studies with reasons 
Author Reason of exclusion 
Adetifa,2009  Prevalence by age 
Amando,2015  No prevalence of breast cancer 
Amir, 1994  No prevalence of breast cancer 
Balekouzou,2016  No denominator 
Bowa 2008  No information on prevalence 
Enow,2012  Total cancer prevalence 
Errahhali,2016  Prevalence of cancer by region in the country. 
Mayi-Tsonga,2009  No denominator 
Obossou 2017  No prevalence of breast cancer 
Okoye, 2017  Prevalence by age only 
Sando,2014  No prevalence rate 
Woldu,2017  No denominator 
 
 
Reasons for the excluded studies based on the title, these studies were not conducted in Africa or were 
not including African patients diagnosed with breast cancer. Studies that were excluded based on 
abstracts they were not including prevalence rate, or their study design did not match our included 
criteria. Finally, the main reason for excluding articles that were reviewed by full text with an 
explanation of the reason for exclusion shown in (Table 2). 
 
4.4.2 Risk of bias assessment 
4.4.2.1 Assessing risk of bias of studies 
The risk of bias assessment was judged by using Hoy criteria modified by Werfalli and colleagues for 
each domain of the 20 included studies (25) (26) (27) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) 
(40) (41) (42) (43) (44) (45) (46). 
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The tool included ten items and rated: 0-5 high risk [Red], 6-8 moderate risk [Yellow] and more than 
8 a low-risk study [ Green]. The result of the risk of bias assessment for the included studies shown in 
(Table 3).    
No studies from our included articles were at high risk. Three studies were of low risk (27)  (34) (36), 
and the rest of moderate risk bias (Table 3). Studies(30) (36) (37) (41) represented a close sample to 
the target population. All the included studies have been using random selection in their sample or 
census was undertaken. Of the 20 articles, only 7 had a minimal of non-response bias. All studies data 
that are included are collected directly from subjects. According to the study instrument that measured 
the parameters (30) (34) (40) were not mentioned, while studies (31) (32) (35) (36) (42) (43) (46) are 
not valid and reliable. All the included studies nominators and denominators were available to 
calculate the prevalence of breast cancer. 
 
4.4.2.2 Assessing risk of bias using Cochrane tools 
We extracted prevalence data from two experimental studies assessing interventions of screening (28) 
(29) of breast cancer from trials conducted in Africa.  These were appraised separately using the 
Cochrane assessment tool for the risk of bias (20). (Figure 3, Table 4) 
Generation of allocation sequence and Allocation concealment for both studies were deemed to be of 
low risk. Risk of selective reporting was low (28) and unclear (29) in the respective studies.  Blinding: 
was not described in sufficient detail and was marked unclear. Incomplete outcome: both studies were 
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Cameroon Sando Low Low Low Low Low Low Low Low Low Low Low 9 
DRC Mvila NCS NCS Low High Low Low NCS Low Low Low Moderate 6 
Egypt  Salem NCS Low Low NCS Low Low Low Low Low Low Moderate 8 
Egypt Denwar NCS High Low NCS Low Low High Low Low Low Moderate 6 
Ghana Agyei-F NCS NCS Low NCS Low Low NCS Low Low Low Moderate 6 
Ghana Naku Low Low Low NCS Low Low Low Low Low Low Moderate 8 
Kenya Sayed NCS NCS Low Low Low Low High Low NCS Low Moderate 6 
Morocco El Fakir High High Low High Low Low High Low Low Low Moderate 6 
Morocco Charaka NCS Low Low High Low Low High Low Low Low Moderate 7 
Morocco Basu Low Low Low NCS Low Low NCS NCS Low Low Moderate 7 
Nigeria Agbo Low High Low High Low Low Low Low Low Low Moderate 8 
Nigeria Ozolio NCS High Low NCS Low Low Low Low Low Low Moderate 7 
RSA Apffel (i) NCS NCS Low Low Low Low Low Low Low Low Moderate 8 
RSA Apffel (ii) NCS NCS Low Low Low Low Low Low Low Low Moderate 8 
Sudan Abudris NCS Low Low Low Low Low Low Low Low Low Moderate 8 
Sudan Saeed Low Low High Low NCS Low Low Low Low Low Low 9 
Tunisia Kiribi NCS NCS Low NCS Low Low Low Low Low Low Moderate 7 
Tunisia Zaanoni NCS Low Low Low Low NCS NCS Low Low Low Low 9 
Tunisia Farika NCS Low Low High Low Low Low Low Low Low Moderate 8 
Zambia Pinder NCS NCS Low High Low Low NCS Low Low Low Moderate 6 
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Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each 
included study. 
Table 4. Risk of bias graph: review authors' judgements about each risk of bias item presented as 
percentages across all included studies. 
Author A B C D E F G 
7.Boulos,2005 Low Low Low Low Un Un Low 
15.Ngoma, 2014 Low Low Un Low Un Un Low 
 
Un = unclear A= Random sequence generation, B=Allocation concealment, C=Blinding participant, D=Blinding of outcome assessment, 
E=Incomplete outcome, F=Selective reporting, G=Other bias 
 
4.4.3 Missing Data 
In this systematic review, none of the authors needed to be contacted since we did not find any 
missing data. 
 
The judgment of the certainty of evidence by using the GRADE approach of included studies. 
Among the intervention studies, we judged the certainty of the evidence as moderate for detecting the 
prevalence of breast cancer. We assessed the certainty of evidence as moderate for the observational 
studies and the combination of total included studies; we assessed the certainty of evidence as 
moderate — our main concerns with the evidence related to study limitations.   
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4.4.4. Data synthesis 
 
4.4.4.1 Overall synthesis 
The overall finding in this systematic review of the prevalence of Breast Cancer in Africa is 0.30 per 
cent, 95% Confidence Interval (CI) (0.26-0.34) test for heterogeneity, I ² = 99.70%; 22 studies, N= 
6x107 participants (Figure 4).  
 
 
Figure 4. The overall prevalence of breast cancer in Africa. 
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4.4.4.2 Gender analysis 
Pooled prevalence estimates by gender revealed 0.49% (95% CI, 0.38 to 0.62) in females versus 
0.03% (95% CI, 0.02 to 0.05) in studies reporting males and females as a single entity. (figure 5). 
 
 
NB: F= female gender, M=male gender. F/M= both sexes included in the studies. 
Figure 5. The prevalence rate of breast cancer in African females. 
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4.4.4.3. Regional analysis 
When considering the studies on a regional basis, rates for breast cancer were highest in the south 
(0.65%, 95% CI (0.24 to 1.26) and western (0.55 (95% CI (0.03 to1.65) regions of Africa (Figure 6).  
While the overall prevalence in central Africa was practically zero, one of the two studies comprising 
the meta-analysis had a high prevalence, probably due to sample size being small in comparison to the 
other.  (Test for heterogeneity, I ² = 99.70%)  
 
Figure 6. The prevalence rate of breast cancer in the five African regions. 
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4.4.4.4 Urban vs Rural 
The pooled prevalence estimates by authors’ descriptions of geographical settings as being rural and 
urban were 0.43% (95% CI, 0.22 to 0.70) and 0.52% (95% CI, 0.11 to 1.23) respectively (figure 7). 
While studies that reported prevalence estimate in both urban and rural geographical regions showed a 
pooled prevalence of estimate of 0.10 (95% CI, 0.06 to 0.14). 
 
NB: N/S= not specific, not mentioned. 
Figure 7: The prevalence of breast cancer by urban vs rural settings 
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4.4.4.5. Study design 
The prevalence estimate for breast cancer in this review was provided by cross-sectional, 
retrospective and trial studies. There was a difference between the pooled prevalence estimates for the 
different study types ranging from 0.01 (95% CI, 0.01to 0.01) for retrospective study designs, 0.37 
(95% CI, 0.30 to 0.42) for cross-sectional, and 0.41 (95% CI, 0.31 to 0.52) for trials (figure8). 
 
CS= cross-sectional studies, Retro=retrospective studies 
Figure 8. The prevalence rate of breast cancer in different study designs. 
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4.4.4.6. Methods used in diagnosis 
When considering the method of breast cancer diagnosis, the pooled prevalence estimates for studies 
using mammography was higher than for clinical breast examination, 0.63 (95% CI, 0.46 to 0.82) and 
0.31 (95% CI, 0.22 to 0.42) respectively. (Figure 9). 
 
CBE=Clinical breast examination, N/D=Not detected, MMG=Examination by mammograms 
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4.4.5  Investigating Heterogeneity 
There was notably large heterogeneity across the studies comprising our meta-analysis. Subgroup 




Summary of main results 
This systematic review of African studies, using a comprehensive search strategy across a number of 
databases and grey literature, without language or specific date restrictions, found the prevalence of 
breast cancer in Africa to be 0.3%.  Our primary aim in this systematic review was to determine the 
prevalence of breast cancer on the African continent in both sexes and for female patients precisely. 
We also sought to report (1) regional differences, if any, (2) which of the African countries provided 
reliable data, (3) differences in prevalence rates in urban and rural settings and finally, (4) the 
prevalence rate of breast cancer according to study design and method used in detecting breast cancer 
from the selected articles.   
 
Overall completeness and applicability of evidence 
Our pooled results calculation of the prevalence rate of breast cancer in Africa was 0.30%. This 
review reiterates the fact that while breast cancer occurs in both genders, it remains rare in males.  
Thus, screening programs specific for males will not make economic sense, and thus particular 
attention must be paid to family history instead,  Breast cancer in Africa is lower than the western 
world; however, both incidence and mortality rates are rising due to lifestyle changes, reproductive 
factors, and increased life expectancy and adaptation westernization lifestyle (47).The prevalence rate 
in African females living in Africa at 0.49% lower than high-income countries (11, 48) (47) (48). This 
may reflect a lack of awareness amongst Africans or a reduced exposure to risk factors.  Of interest, 
the prevalence was highest in the south African region, thus pointing to the increased exposure to risk 
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Our findings highlight the paucity of data across the continent on one of the most critical cancers 
affecting women in most of the African countries and around the world. Almost half of the data for 
this review was provided by studies in North Africa. Central Africa was only represented by two 
studies (13,19).  In addition to lacking active population-based cancer registries, most of the registries 
cover a small part of its population and do not meet high-quality registration standards (49) (50) (51). 
Adding to that, politically unstable countries, struggling with many other diseases and more 
concerning health issues causing a heavy load, compounds the difficulty in addressing the breast 
cancer burden (7).  
 
When taking in the account of different settings between rural and urban areas; we have found more 
patients diagnosed with breast cancer in the urban areas, which could be explained by more awareness 
of female in these regions or because of easily accessible medical facilities in the major cities. On the 
other hand, prevalence rates in rural areas of Africa are fewer than the urban parts and fewer women 
in these regions seeking medical advice. Socio-cultural barriers could explain the lower prevalence 
rate and believes, lack of health care trained personnel, limitation of diagnostic facilities, and 
expensive treatment (18) (52) (53).  
  
Our analysis of study design showed a lowered prevalence rate in retrospective studies, further 
emphasizing the need for well-designed prospective registries.  Screening with mammograms is 
considered the gold standard for early breast cancer detection.  Only six studies screened for breast 
cancer with mammography for women above the age of 40 years in three African countries (Tunisia, 
Egypt, and South Africa) reporting a combined prevalence rate of breast cancer of 0.63 (95% CI,0.46 
to 0.82). These results, with only a small section of the population being covered, emphasize the need 
to implement population-based screening programs. Mammography screening for breast cancer has a 
sensitivity of 63 to 95%, and it is the only examination tool and considered the gold standard for early 
detection demonstrated to decrease in mortality rates in ages 50 years and above (54) (55). Its 
sensitivity increases with the presence of palpable lumps while the sensitivity decreases when 
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examining women with high dense breasts. Recent studies have been contributing the reduction of 
mortality rates in many developed countries to mammography screening programs (56). 
  
 In Africa, with its low income and weak health systems, population-based screening barely exists.  
Because breast cancer in African women develops at a young age, and because mammogram 
examinations are not performed before the age of forty years, an alternative cheap and available 
technique is used.  Clinical breast examination (CBE) alongside breast ultrasound was used in most of 
our studies, giving a prevalence rate of 0.31%. Despite clinical breast examination only detecting 




Our systematic review is the first to calculate the prevalence of breast cancer in Africa. 
One of the main strengths of this review is that we have systematically and vigorously performed the 
comprehensive search of multiple electronic databases using an African search filter. Furthermore, we 
have included all the data available with no language or time restriction to identify multiple 
publications. As suggested by the PRISMA guidelines statement, we have appraised the 
methodological quality of individual studies by using the standard quality assessment tools for 




Studies on early detection using screening of breast cancer are limited in the literature in most of the 
African regions. Of the included studies, there were only 12 countries from 54 which provided the 
prevalence rate for breast cancer in Africa. The remaining African countries have not been reporting 
any data on the prevalence of breast cancer nor have embarked on any screening for the 
population. Furthermore, the majority of the studies included in this systematic review used clinical 
breast examination for the screening of breast cancer as an alternative method, therefore, results of 
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prevalence rate can be underestimated because the screening purpose is to detect non-symptomatic 
lesions to prolong survival rates.  
 
The large heterogeneity found amongst our studies was to be expected, as is often the case in prevalence 
meta-analyses with variation in study design.  Exploring subgroup analyses did not alter the 
heterogeneity. The assessment of risk of bias showed low levels of risk and thus, we feel that the current 
study nevertheless provides the best estimates to date. 
 
 
4.6 Conclusion  
Studies that focus on the pattern of prevalence of breast cancer across Africa are limited. To our 
knowledge, this is the first study to address the prevalence of breast cancer on the African 
continent. Only 12 countries provided data for the calculation of the prevalence rate of breast cancer 
in Africa. Less than half of the African countries have active cancer registries; however, the quality 
and completeness of data are not equal to standard registries and only cover a small part of population 
groups. A massive effort and more resources are needed to address the burden of breast cancer in 
Africa, where incidence rates and mortality rates are increasing. 
 
4.7 Recommendations 
4.7.1 Implications for practice 
We found that the prevalence of breast cancer studies in Africa is limited and the meta-analysis is low 
compared with high-income regions. However, the findings of this study will provide important 
baseline information for clinicians, health care workers, and policymakers regarding the burden of 
breast cancer in Africa. 
 
4.7.2 Implication for research 
This work serves to recommend prioritizing further research regarding the causes and methods of 
early diagnosis of breast cancer since it severely affects women at an early age. Because 
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mammography screening is not recommended to diagnose a breast lesion in young age groups, an 
alternative affordable method should be adopted in a low resource setting, and investment in cancer 
control is needed. 
 
4.8 Ethics and Dissemination 
This systematic review relied on secondary data that is accessible to the public and did not require 
formal ethical review [33]. The study protocol was reviewed and submitted to the University of Cape 
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REF:561/2018). The waiver is provided in the appendix.  
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Appendix 4.5, Quality assessment criteria for Prevalence studies. 
External validity  
1.Was the study’s target population a close representation of the national population in relation to 
relevant variables? (1 point) 
2. Was the sampling frame a true or close representation of the target population? (1 point) 
3. Was some form of random selection used to select the sample, OR was a census undertaken? (1 
point)  
4. Was the likelihood of nonresponse bias minimal? (1 point)  
Total points (4 points)  
Internal validity  
1.Were data collected directly from the subjects (as opposed to a proxy)? (1 point) 
2. Was an acceptable case definition used in the study? (1 point) 
3. Was the study instrument that measured the parameter of interest shown to have validity and 
reliability? (1 point) 
4. Was the same mode of data collection used for all subjects? (1 point) 
5. Was the length of the shortest prevalence period for the parameter of interest appropriate? (1 point)  
6. Were the numerator(s) and denominator(s) for the parameter of interest appropriate? (1 point)  
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Appendix4. 6, Checklist items.  
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  69 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, 
and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
70 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  49 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  49 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  50 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  52 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  51 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  51 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  53 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  53 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  50 
Risk of bias in individual 
studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.  53 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  52 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
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From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The 
PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  





Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  55 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-
specified.  56 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally 
with a flow diagram.  71 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  76 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  81 
Results of individual 
studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  82 - 91 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  82 - 91 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  80 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  91 – 96 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., 
healthcare providers, users, and policy makers).  98 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, 
reporting bias).  100 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  101 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.  56 
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5.1 Cancer registries 
Cancer is a growing health problem causing high morbidity and mortality around the world. In 2018 there 
were an estimate of 18.1 million new cancer cases and 9.6 million deaths. Unfortunately, from the total 
cancer deaths, 70% were reported from low-and-middle-income countries  (1) (2) (3) (4) (5) (6). Lack of 
basic health services, population growth, ageing, adaptation of an unhealthy lifestyle, and environmental 
changes contributes to a heavy cancer burden (1) (4) (5) (6) (7). Information such as number of cases, 
distribution, type of cancer, methods of diagnosis, cancer staging, the treatment used, and patient 
outcomes are fundamental in planning and monitoring cancer management programs (1) (6) (7) (8) (9). 
This information can be provided by comprehensive, well planned-out cancer registries although 
collecting this detailed information requires enormous staff effort, money, time, and continuation (9) (10)  
(11) (12) (13) (14). 
 
5.1.1 Definition of cancer registries 
A cancer registry is a type of disease registry, defined by the continuous, systematic collection, storing, 
summarizing and distribution of data on cancer occurrence and its detailed characteristics of patients 
living in a geographical area. A cancer registry is a long-term health information system useful for 
measuring the size of the problem and allows one to evaluate the performance and improve the 
management plans of public health approaches. The registry records patient details, which are available 
only for authorized individuals: therefore, patient confidentiality is assured; patients name and details will 
be displayed only as a code to the public (10) (11) (12) (13) (14) (15) (16) (17) (18). 
 
 
5.1.2 Cancer registry aims  
The primary purpose of such a registry is to provide an ongoing record of cancer cases for cancer 
researchers to detect the risks and causes of malignancies. Another important reason for the cancer 
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registry is to provide critical and accurate information to health officials in planning and evaluating 
cancer control and prevention programs (1) (3) (4) (10) (13). 
 
5.1.3 Types of cancer registries 
There are four types of cancer registries: hospital-based, population-based, pathology-based, and special 
purpose cancer registries (9) (17) (18) (19). 
 
5.1.3.1 Hospital-based cancer registry 
These registries are based on hospital records; cancer patient information in detailed; they are more 
commonly used than the population-based registry. The first hospital-based cancer registry was 
established in Connecticut, United States in 1926 to report cancer cases. They provide us with full 
detailed methods of diagnosis, treatment received, and the result of the treatment of a cancer patient. They 
usually report the number of cancer cases seen in the specific unit or hospital per year. These records will 
calculate the incidence of specific cancer compared to total cancer case admitted in the same hospital in a 
specific time. Therefore, the recorded information can be used instantly to provide future services needed 
in a given unit or hospital. Despite that, the occurrence and burden of cancer of the total population is not 
calculated. They usually limit sharing their information between hospitals; cases can be recorded multiple 
times in different hospitals, masking the actual cancer count in the community. Another essential 
drawback is that collected information may differ from health service to another; therefore, comparing 
findings may be difficult (10) (13) (17) (19). 
 
5.1.3.2 Population-based cancer registry 
“Population-based cancer registry data [are] an essential foundation of national cancer control planning 
– if you do not know your cancer burden, how can scarce resources be targeted at the most appropriate 
solutions for cancer?” 
Dr Eduardo Cazap (Argentina), Past President, Union for International Cancer Control 
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The first functional population-based cancer registry was documented in Germany in 1926, although there 
have been many attempts through Europe before, these failed to accomplish their mission. There are more 
than 290 cancer registries around the world now, mainly in high-income countries. However, only a few 
covers the total population (5) (7) (8). From its name, they include all cases of cancer in the population 
over some time. These registries contain data collected from multiple sources, such as cancer centres, 
hospitals, private clinic, hospices, homes and shelters, pathology units, imaging centres, and death 
certificates registries. Population-cancer registries serve a more extensive range of services compare to 
other types of cancer registries. However, assessing and covering high-quality data when a large number 
of the population are involved can be difficult in continuing providing data (19).  
 
These population-based cancer registries are exceptional resources for an epidemiologist; they provide the 
distribution of cancer in a selected population, which includes the incidence and prevalence. Another 
significant benefit from population-based cancer registry is the calculation of survival rates, which are 
useful in assessing advances in treatment. However, collected data can differ from one registry to another, 
causing difficulties in the comparison between groups of the population (15) (16) (17). 
 
Cancer patients are followed for long periods until death, either due to cancer or other causes.  These data 
are used for developing and supporting critical research, which could evaluate and assess control 
programs, screening methods, and its effectiveness for early detection of cancer lesions in reducing the 
mortality. However, population cancer registries require existing medical facilities and full cooperation 
medical staff in the community, which can require a long time and is costly. 
 
An advantage in performing a population-based cancer registry, is that their data are vital to ensure health 
officials have accurate information to allocate funds, human resources and proper facilities. At the same 
time, they require support from regular and accurate census programs in parallel. This registry does not 
make sense unless the denominator of the population is available and able to identify nonresidents from 
Chapter 5 5  
residential in the target population. Therefore, regional registries would be more effective in countries 
with larger population sizes (17) (18) (19). 
 
5.1.3.3 Pathology-based cancer registry 
In this type of registry, the data is collected from histologically diagnosed cancer, and they provide a 
quick cancer profile. However, the population from which the tumour tissues derived is not defined (10)  
(11) (17). Pathology based cancer registry can provide essential clues to determine the burden of cancer in 
a community. Nevertheless, they are prone to bias since they can underestimate cancer cases. However, in 
a low resource setting, this type of registry may be the only source in providing cancer information. 
 
5.1.3.4 Special- purpose registry 
This type of registry collects information on one type of cancer, for example, breast cancer or specific age 
group abnormality (17). They provide educational opportunities to learn more about a specific type of 
cancer and plan supportive measures for those affected in the population. Although they are very rich in 
detailed cancer information, these type registries are not typical, and only a few have been established. 
 
In conclusion, all types of cancer registries are of great value for individual and community health care. 
Together they provide us with the complete picture of all the essential information that is related to plan, 
evaluate, and control cancer burden. 
 
5.2 African cancer registries 
The cancer burden is increasing in Africa, require urgent initiation and functioning high-quality 
population-based cancer registry systems to provide evidence-based cancer control program. At the 
moment, only a few have been selected to submit their data. In Africa, there are eight countries: Algeria 
Egypt, Libya, Tunisia, Malawi, South Africa, Uganda, and Zimbabwe, report an annual high-quality 
incidence data; however, only four provide mortality statistics in Africa (9). 
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The African Cancer Registry Network (ACRN) has launched on the first of March in 2012, partnered 
with the International Agency for Research Cancer (IARC) to improve cancer surveillance in the Sub-
Saharan region. More than 20 countries registered from the Sub-Saharan region and started providing data 
capable of assessing control measures. In contrast, 19 countries from Africa have no incidence or 
mortality cancer data (5) (11) (18). 
 
5.2.1 The Benghazi, Libya cancer registry 
The Benghazi cancer registry was established in 2002 and provide cancer incidence from eastern Libya, 
covering 28% of the total population. This registry, as most of the African country registries, partnered 
with IARC. The result from this registry showed that the pattern of the incidence of many cancers differs 
from estimated figures based on neighbouring countries data. The registry provides an annual report of 
cancer incidence and important trends are available to the department of health. The presentation of data 
can initiate cancer research projects in the coming future to overcome cancer burden (18, 20). 
 
5.3 The Libyan breast cancer registry 
5.3.1 Introduction 
There were 2.1 million new diagnosed females with breast cancer in the year 2018. Breast cancer has 
become the most frequently diagnosed cancer around the world and contributing about 25.4% of all total 
new cancer cases in women. The highest recorded incidence rates were from Australia/ New Zealand, 
most of Europe and North America. This cancer has caused over a half million deaths in both sexes, the 
highest country reporting the most mortality rates from breast cancer was Fiji in 2018 (1). Unfortunately, 
the majority of deaths from breast cancer occurred in both middle and low-income countries, with women 
diagnosed at a late stage and early age, with a lack of awareness and poor early detection plans, therefore, 
the survival rate is low (1) (21) (22) (23) (24).The lowest recorded five-year survival rates were in the 
Gambia, Western African region, in which only 12% of women survive the five years after diagnosis with 
breast cancer (25) (26). 
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On the other hand, females living in the high-income countries have a prolonged five-year survival rates 
that reaches more than 85-90% in certain countries, particularly French, Danish, and Japanese women. 
While in North American and Canadian women, 85% survive ten years after diagnosis of a localized 
cancer lesion that has not spread beyond the breast tissue  (1).  This prolongation of survival rate in high-
income countries can be explained by the availability of both awareness and early detection screening 
programs — also, the availability of a variety of cancer medication and availability of cancer 
rehabilitation centers (1) (27) (28) (29). 
 
Both men and women can get the disease; however, breast cancer in males is quite rare, accounting for 
less than 1% of all breast cancer around the world (30) (31) (32) (33) (34). The male to female ratio is 1: 
100 in the United States and Denmark, while in Sub-Saharan Africa report from a large meta-analysis 
showed a high male to female ratio 1:14 (1) (30) (35). The risk factors associated with developing breast 
cancer in males are similar to females in that they increase with age and having a family member with the 
disease. However, the average age is around a decade older than in females. Outcomes of male breast 
cancer are reportedly worse than females, however, because of lacking extensive population studies, the 
rarity of the disease and missing complete data, management plans regarding breast cancer are unclear for 
males diagnosed with breast cancer (33) (34). 
 
In Africa, due to rise in population numbers and life expectancy, exposure to risk factors and weak health 
care system is associated with a rise in cancer incidence rates (22) (23). The incidence of breast cancer in 
Africa from population-based registries was ranging from 29.3% in North Africa, and 22.4% from Sub-
Sub-Saharan region (35). Although the African continent is a mixture of multiple ethnicity, women share 
the same characteristic in poor outcome after developing breast cancer. African women develop breast 
cancer at an early age, and they present at a late stage, resulting in limiting treatment options and causing 
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more exposure to toxins from anti-cancer treatment leading to an increasing of both morbidity and 
mortality (19) (21) (23). 
 
Libya is the fourth largest African country located in North of Africa on the southern shore of the 
Mediterranean Sea. With a population of 6,278,000 (2006) Libya is one of the lowest population density 
countries in the world and labelled as one of the upper-middle-class income countries in Africa. However, 
despite being a wealthy country, Libya is facing severe health care problems. Nowadays, many Libyans 
are adopting unhealthy lifestyles such as consuming more fatty food, less fibre, less physical activity, 
smoking tobacco, and drinking alcohol. This change in lifestyle together with environmental changes and 
high life expectancy are perhaps the causes in rising cancer rates. Primary cancer prevention programs 
such as tobacco control, alcohol control, obesity prevention, and promotion physical activity are minimal 
to non-existent (20) (29) (30). Lacking training persons in all health divisions, inactive public awareness 
programs, no screening methods implemented, weak health departments, continuous instability of 
government and carelessness of patient are all part of the enormous struggles facing Libya today. 
 
There are two national cancer institutes and three oncology and haematology departments in Libya; 
unfortunately, they are only distributed in the Northern part of the country in the major cities. Even 
though these centres cover the majority of the Libyan population, the remaining rural areas are not 
reachable. These centers provide full cancer facilities such as radiation units, diagnostic pathology 
laboratories, surgical theatres but only one positron emission tomography scanner for the total 
population is available. 
 
Despite the free healthcare in Libya, cancer remains a low priority, and patients seek medical advice at a 
late stage, as observed in many regions in Africa. In addition, because of Libya’s conservative society, 
several social and cultural factors affect those seeking western medication and prefer alternative medicine 
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(36) (37) (38). This pattern of seeking medical support at a late stage minimizes the treatment options for 
clinicians in controlling cancer and results in more aggressive radical surgery rather than primary lesion 
removal, and increased exposure to more toxins from receiving anti-cancer treatment for metastatic 
lesions ; together these results in  a rise in both morbidity and mortality rates (35, 39). 
 
In 2002 the first population-based cancer registry published its data from Benghazi Medical Center 
reveals that the most common cancer among Libyan females was breast cancer.  However, these 
results were only covering 28% of the total population. Results from the population cancer registry 
reported that breast cancer represents 26 % of all cancer types (39) (40). The latest incidence rates of 
female breast cancer were 23.2 %, breast cancer caused a total of 15% of all cancer-related deaths in 
females (18). Meanwhile, hospital-based cancer registries have revealed that breast cancer new cases had 
increased slightly in 2018. The results of breast cancer incidence in females are 23.8% for all ages and 
caused 14.9% mortalities in the same year (41) (42) (43) (44). 
Breast cancer is more prevalent in younger age groups with a median age of 44 years, mainly during the 
pre-menopause period around ten years younger than in high-income countries and similar to most of the 
African region (18) (41) (42) (43) (44). In contrast, the mean age group in males is 61 years; as 
previously mentioned men are usually seen at medical facilities only in an advanced stage. The overall 
five-year survival rates are 57% for men compared to females 78%, which is more than most parts of 
Africa (25) (40) (41) (42) (43) (44). 
 
In Libya, the management plans are similar and updated according to the national cancer management 
plans. Breast cancer is managed by a multidisciplinary team that consists of a surgical oncologist, medical 
oncologist, and radiotherapist. The team discusses each patient separately, and a management plan offered 
to the patient. This plan includes considering the health status of the patient and stage of the disease. 
However, cancer medications, permanent oncologists and palliative care centers may not be available. 
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Proper surveillance programs are mandatory to monitor cancer trends; high-quality record-keeping and 
evaluation of methods of early diagnosis in high-risk groups are crucial to upgrade management plans.  
More attention and effort should take place in improving patient awareness programs, starting in small 
community villages and expand through the country. Education of risk factors causing cancers and 
explanation of early symptoms and signs and its importance in early seeking medical advice are 
mandatory. Training medical health persons for cancer diagnosis and early referrals can improve the 
quality of life of cancer patients. Together with updating of advanced diagnostic techniques, providing 
cancer treatment drugs, all together to improve patient quality living and rise in healthcare in Libya. 
 
 
5.4 Libyan Breast cancer report Form 
5.4.1 Aims: 
A breast cancer registry is a special purpose registry that collects exhaustive, detailed information from 
patients diagnosed with breast cancer. The main aim of developing a Libyan breast cancer registry is to 
provide an opportunity to learn more about the disease development, the changes through the course of 
the patient's life and outcomes that serve as an information resource for cancer research. Secondly, we 
will be able to track the incidence, mortality and survival of patients diagnosed with breast cancer and 
their distribution in Libya. Finally, the information will be translated into figures to help plan supportive 
measures and control to those effected and at high risk for improving breast health care in Libya. 
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5.4.2 Designing the form: 
We have collected a comprehensive set of information for breast cancer. Information relevant to breast 
cancer was summarized into simple questions that can be answered by both the registry team and the 
patient. These information’s are useful to show whether performing the usual screening programs or the 
existing methods and prevention attempts are making a difference for cancer control. 
 
5.4.3 Content of the Libyan Breast Cancer Registry Form: 
5.4.3.1 Manual of operations 
The manual of operations intends to guide the registry team to identify and record results specific for 
breast cancer patients. In this section, there is a full explanation of how to answer and fill in the questions. 
Examples answered, and details of contacts are included in the manual in case of any clarity is required. 
(Appendix 1 LBCR 7, page 5) 
 
5.4.3.2 The forms 
There are three parts for the registry form I, II, AND III.  
I- This part consists of demographic data and cancer information. The main detail consists of patient 
personal data which consists of patients' medical history, general examination, breast examination, 
methods and results of the diagnosis, and the treatment offered. (Appendix 1 LBCR 9.2, page 21-37) 
 
II- Follow up sheet that used for continuous follow-up _ each time the patient is advised to visit a new 
follow up form is completed. All new information regarding patients’ details, new complaints and 
investigation findings and any changes or treatment offered at the visit, are recorded in this section. 
(Appendix 1 LBCR 9.2, page 38-44) 
III- Death information sheet, details of deceased recorded accompanied with a copy of the actual death 
certificate, and an autopsy report in case it was required. (Appendix 1 LBCR 9.2, page 45-46) 
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5.4.3.3 Appendices  
Additionally, to the above, the appendices will contain the consent form in both English and Arabic 
languages, the international occupation list, BIRADS table for mammography readings, cytology table for 
fine needle aspiration results, and TNM classification. 
 
5.5 Reporting  
The registry team will be provided with a working space with the required equipment and facilities to 
ensure following the correct procedures in the registry. Furthermore, the registry team will be trained and 
updated regularly to secure the reporting system is parallel with the international registry. A budget will 
be placed to guarantee the continuation of the registration of the team members and no missing of patients 
recording or dropping periods (9) (10) (11). 
 
At the start, printed copies will be distributed between registry teams for practice, calculate the required 
time needed to fill in the forms, and piloting to ensure no missing information, and ready for the 
electronic version. The printed copies will guarantee a backup in case of no electronic documentation 
available for any reason, such as a shortage of electric power or destruction of files. However, this method 
will consume team members' time to complete, and duplications of patients are frequent with this type of 
documentation. Besides, paper documents require more office space to be stored, misplaced, lost, and are 
risk of exposing patients' privacy. Furthermore, accessing copies is difficult from other places without 
physically going to the location (11) (12). 
 
An electronic capturing of patients' information will be placed and activated at the same time printed 
copies are filled, to ensure smooth patient recording. As soon as the process familiar with the registry 
team, electronic data recording will take over. Electronic forms filling will save time for team members. 
The correction of electronic forms mistakes without the need for repeating another copy, changes are 
made fast and can be saved instantly. Also, the duplication of patients avoided because the data stored for 
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the same patient will appear immediately. Furthermore, registry files can be duplicated and stored easily 
to ensure backup data prevent loss or file corruption. Besides, effortlessly sending reports between the 
registry team, saving time and money (13) (14) (15) (17). 
 
5.6 Objectives : 
Each part of the LBCR will be addressing the following objectives: 
 
LBCR Form I: Baseline form 
• To describe the demographic characteristics and presenting features of Libyan breast cancer 
patients. 
• To compare disease occurrence in different groups and by regions within the country. 
• To list details of known and possible related risk factors such as family history, type of food used, 
occupation of patients and associated medical problems. 
• To describe available screening methods used and to measure how effective these are in the early 
detection of breast cancer. 
• To measure the common tumors types diagnosed and their specific characteristics of Libyan 
breast cancer patients. 
• To stage disease presentation, time of diagnosis of patients, and timing of seeking management 
care. 
• To monitor guidelines followed in the management plan from the investigation, procedures, and 
treatments used locally for both early and advanced breast cancer patients. 
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Form II LBCR: Follow-up form 
• To determine the recurrence rate and cancer status of breast cancer patients. 
• To determine the effect of treatment used and related complications. 
• To describe the different stages of five-year and ten-year survival of patients after diagnosed with 
breast cancer. 
• To determine the development of new types of breast and other cancer. 
 
Form III LBCR: Deceased form 
• To quantify the annual breast cancer mortality rate.  
• To determine the age of death with breast cancer. 
• To determine the regional distribution of morbidity and mortality rates in the country. 
 
5.7 The implication of the LBCR registry: 
Implications for the clinical practice: 
• This registry will to serve as a notification and reporting system used for breast cancer incidence, 
prevalence, and trends through appropriately designed studies that will be generalizable to the 
whole population of Libya. 
• We hope to empower breast cancer patients through information and data on breast cancer 
treatments in Libya 
• This registry will assist medical professionals to generate reports tailored to guide and improve 
outcomes of Libyan breast cancer patients.  
• To set a model for other cancer registries to guide other cancer control plans in Libya. 
 
Implications for future research: 
• Identify key areas that could be targeted to improve outcomes. 
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• Data within registries provide an ideal platform for new research and policy initiatives to improve 
the quality of health systems in Libya. 
• Further research should be strongly encouraged for simple and effective tools for early breast 
cancer screening.  
• Collaborate with other research agencies/institutions on breast cancer studies. 
 
Implications for policy Advocacy: 
• Highlight primary preventive measures related to available risk factors in developing breast cancer. 
• Suggest secondary preventive measures in designing better breast cancer early detection methods 
specific for high-risk populations and early age groups.  
• Advocate for awareness campaign programs and support patients diagnosed with breast cancer 
through there life journey. 
• Collaborate with national and international organizations to help improve breast cancer care in 
Libya.  
• Influence decision-makers to set priorities and not to waste precious resources to overcome breast 
cancer in Libya. 
 
5.8 Conclusion: 
The clinical picture of breast cancer in Libya differs from Western countries due to the high proportion of 
patients develop the disease at a younger age and seek management care at an advanced stage. The 
Libyan breast cancer registry is the initial step to provide all the essential information that is related to 
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2. CONTENTS OF THE LIBYAN BREAST CANCER REGISTRY FORM 
 
 
1. Front cover 
2. Contents of the LBCR 
3. Abbreviations. 
4. Inclusion criteria. 
5. Exclusion criteria. 
6. Patient Confidentiality. 
7. Manual of answering the form: 
7.1. General information for completing the LBCR 
 
             8. Contents of each section: 
8.. LBCRF(i) 
• Participant personal data and medical history 
• General examination of the participant; 
• Breast examination of the participant: 
• Methods and results of diagnosis: 
• Treatment offered to the participant 
8.B. LBCRF (ii) 
8.C. LBCRF (iii)  
9. Appendices: 
9.A. Tables for LBCR 
• Table T1: Occupation classification table 
• Table T2: BIRDS classifications table 
• Table T3: Cytology FNA classification 
• Table T4: TNM clinical and pathological classification 
9.B. Templets for LBCR: 
S1. The LBC Registry Form (i). 
S2. The follow up / visit form of LBCR (ii). 
S3. Deceased form of the LBCR (iii). 
S4. Informed Consent. 
• S4. a. Informed consent in the English language 
• S4. b. Informed consent in the Arabic language 












• ALND = Axillary lymph node dissection. 
• BI-RADS = Breast Imaging Reporting and Data System 
• BMI = Body mass index. 
• BRCA 1/2 = Breast cancer gene 1 and Breast cancer gene 2. 
• BCS = Breast conserving surgery. 
• C50 = Breast cancer code ICD 
• BSE= Breast self-examination. 
• CBE= Clinical breast examination 
• cm = Centimeter. 
CT scan = Computed tomography 
• C = Cytology diagnosis based on microscopic examination of cells. 
• DCIS = Ductal Carcinoma In Situ. 
• ER = Estrogen receptor. 
• FNA= Fine Needle Aspiration. 
• G = Gravida (total number of confirmed pregnancies regardless of the outcome of the 
pregnancy) 
• HRT = Hormonal Replacement Therapy. 
• HER2 = Human Epidermal Growth Receptor 2. 
• ICD = International Classification of Diseases  
• ILC = Invasive Lobular Carcinoma. 
• IDC = Invasive Ductal Carcinoma. 
• In Situ = Cancer cells not progressed through the basement membrane. 
• Kg = Kilogram. 
• LBCR = Libyan Breast Cancer Registry. 
• LBCRF = Libyan Breast Cancer Registry Form. 
• LCIS = Lobular Carcinoma In Situ. 
• LN = Lymph Nodes. 
• MRI = Magnetic resonance imaging. 
• mm = millimeters. 
• mmHg = millimeter mercury. 
• -ve = Negative. 
• P = Parity (number of pregnancies a woman has given birth to alive or lost, fetus more than 
20 more than weeks)   
• PET scan = Positron Emission Tomography 
• PR = Progesterone receptor 
• +ve = Positive. 
• RSA = Republic of South Africa. 
• SLN = Sentinel lymph nodes. 
• SLNB = Sentinel lymph node biopsy. 
• TNM / T=Extent of the tumor, N=Regional lymph node metastasis, M=Distant metastasis. 
• U/S = Ultrasound. 





4. INCLUSION CRITERIA 
All criteria must be present: 
• Participation must sign a consent form. 
• A histopathology report must make the diagnosis of breast cancer. 
• Registry for both male and females’ participants diagnosed with breast cancer. 
• All age groups diagnosed with breast cancer included in this registry. 
 
5. EXCLUSION CRITERIA 
Do not proceed for registration if: 
• No consent forms. 
• Diagnosis without a histopathology report. 




• Written informed consent must be obtained before enrolling participation (A template 
informed consent included in the appendices in both English and Arabic languages S4A, 
S4B).  
• If the participant cannot read or write, a thumbprint will be sufficient, and a witness must 
be present to sign the form. 
 
 
6. PATIENT CONFIDENTIALITY 
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Participant personal data kept away from the public; the participant name will be de-identified. 
Data will be key coded. The forms will be locked in a secured place accessed only by the 
registration team members. Any required information about the registry form participant can 
contact the registry staff. Details of contact names and cell phone numbers of LBCR coordinators 
will be in section 9 of the manual of operation. 
 
7. MANUAL OF ANSWERING THE FORM 
7.1. General information to be followed to complete the registry form: 
• For the person filling in the form: Please read the manual carefully and follow the instruction for 
each section. 
• Forms must be filled correctly; please take time to fill the form as all details that are asked are 
crucial, and this information will be used in an attempt to help a patient suffering from breast 
cancer. 
• Forms must be completed with a black colored pen, NOT with a pencil or any other color, please 
fill the form by writing from left to right in the English section and from right to left in the Arabic 
section. 
• Ensure that the participant meets the eligibility criteria and exclusion criteria not applied. 
• If a consent form is not filled and signed by the participant/family member, please do not 
proceed. 
• The participant or relative responsible for providing any required information must sign and 
record his/her document. 
• If the participant cannot write or read, then relative details must be filled in the given section, 
his/her signature, address, and telephone numbers must be documented for any further 
information. 
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• If the participant is given a verbal consent and cannot write a fingerprint of the participant will be 
sufficient; if the fingerprint is not applicable, witness details should be present to confirm a verbal 
consent. 
• After the consent form completed, start filling all the pages and follow the instruction of each 
question carefully. 
• Please make sure that all pages available, numbered in a sequence, and fill accordingly. This part 
of the information is critical for data quality. Each page must be filled and checked for all 
sections. Please take the time to complete the diagrams of both breasts by drawing the site of 
tumor and lymph nodes or any other findings. Complete the family pedigree by using the 
available codes in the same sections; look at the examples provided in the given sections. 
• In case of any changes on the form, only cross the previous information without writing on the 
crossed site. Write the initial of the person, corrected the information, and fill in the date in the 
given space or comments. Do not use correction fluid. 
• There will be a space to comment or to add an essential message for each question. Please write 
neatly and legibly in the given space. 
• If the participant does not complete the follow-up, an attempt via telephone must be made to 
remind the participant for the date of follow-up, and all notes must be documented. If the 
participant does not respond, a family member of the participant will be contacted for completing 
missing data. 
• Please update all-new details of the participant and the new details of the person responsible for 
filling the form for each visit. 
• When question heading does not indicate more than one answer, only mark one answer. 
• The person filing the form initial: the first letter of his/her name in the first box, the middle name 
first letter in the second box, and the last name first letter in the third box, as shown below.  
• The initials are repeated on each page with participant ID, e.g. (Name of the doctor filling the 
form is: Ahmad Nori Abdulsalam). 
|_A_|_N_|_A_| 
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• If the person does not have a middle name, place a (-) in the middlebox, as shown. (Name of the 
doctor filling the form is: Khalid Daw). 
|_K_|_-_|_D_| 
• In the giving boxes, please mark the specific answer with an X in the box instead of ✔ 
e.g., (The participant is a Male). 
|_X_| Male 
       |_ _| Female 
And Not, e.g. (The participant is a Male). 
!_√!Male 
|__| Female 
• When writing the date, start filling from left to right, the first two digits are the days of the month, 
the second two for the month in numbers, and the last four digits for the year: Please write above 
the light letters DD /MM /YYYY. 
e.g. (Date of birth of participant is on the third of February 1976). 
Date of Birth: 03 /02 /1976. 
• In case the answer is two digits, and there are three boxes available, fill the first number with 
zero.  
e.g. (If the patient’s pulse rate is 79 beats/ min fill the boxes as shown). 
|_0_|_7_|_9_| beats/min. 
• Please take the time to fill the diagrams provided in each form and measure the required parts 
when needed. 
• For the family pedigree, use the provided codes and fill accordingly. The P is for the Participant: 
if the participant is a male, draw a square around the [P]. If the participant is a female, draw a 
circle around the ℗. Family members with positive breast cancer must be placed in the diagram 
to indicate the relation to the participant, and please indicate the sex of relative with positive 
cancer. 
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e.g. (A 50-year- old female participant diagnosed with breast cancer has three daughters and three 
sons. Had a maternal grandmother who died with the same disease and two of her daughters are 
receiving chemotherapy for breast cancer in the oncology unit). 
 
 
• In the breast cancer diagram, draw the lesion the participant had before any procedure in the 
LBCR(i). Indicate the site of lesions, any changes or findings such as scars, new lesions in each 
visit in the LBCR form (ii). Please do not forget the measurements of both upper limbs for each 
visit. e.g., A female participant diagnosed with left side breast cancer operated with a left 




8. CONTENTS OF EACH SECTION 
• The LBCR manual of operation that explains how the required data are collected. It also 
contains all the required tables to answer any detailed information regarding breast cancer. The 
appendices of LBCR contain the consent form in both languages English and Arabic. 
Furthermore, the contact information of staff members will be available for any clarity, 
comments, and advice. 
• LBCR (i), this part focuses on all the details of the participant personal information, personal 
history, family history, method of diagnosis, and treatment received. 
• LBCR (ii) is the follow-up form, condition of the patient asked, any new complaint, any change 
of management plan is all included in this part of the registry. For each visit, a new form filled 
with newly updated data for the participant. 
• LBCR (iii) contains the deceased form, when the participant passes the information will either be 
collected from hospital files, the doctor in charge or family member. 
8.I LBCR(I) 
• This part consists of 17 pages; each page contains the page number from 1-17, the participant's 
ID, ICD code for breast cancer C50, and the doctor filling the form initials. The questions 
divided into 21 sections from A-U; each section has subtitles, and space is provided to fill-in the 
answers. 
• Section A: The registry members give the participant ID case in a sequencing method. If the 
participant has another primary breast cancer should be cleared and documented in the given 
space. 
• Section B: The person filing the form details must be included, in case of any missing data or any 
clarity needed can be solved by contacting him/her. 
• Section C: Participant reliable relative full name, relation, and cell phone number are asked and 
filled in the given space. The relative contacted in case the participant has missed a visit, or the 
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participant has lost contact. Also, if a participant cannot read or write, a relative can sign the 
consent form after the patient's verbal permission. 
• Section D: consist of question-related to the full participant name, address, age, date of birth, 
country of birth, and marital status. Nationality of the participant included, and more details asked 
for Libyan patients. Religion, level of education, and type of occupation asked. The type of 
occupation filled from the national occupation classification table in the appendices (T1).  
•   Section E: This part of the form is asking details regarding participant personal habits. Details 
such as: if the participant smokes, drinks alcohol, and sleeping routines. The last section on this 
page is asking about the type of food; the participant is taken food that is common in the Libyan 
culture on a daily basis. The amount of food suggested is roughly measured and found on the 
same table. 
• Section F (i): This section can have multiple answers to choose from if the participant is known 
for any medical diseases, the age the medical condition started, is the participant taken regular 
medication all must be filled. Finally, space provided for any changes that happened or any 
comments.  
• Section F (ii): In this part of the registry, we are asking about any procedure/ operation the 
participant had, also if the participant had a history of cancer type and treatment that he/she 
received.Document any past trauma to the chest wall. 
• Section G (i): This section is asking for any family history of cancer, especially breast and 
ovarian cancer. We also like to understand if any genetic counseling was done in cases of positive 
breast/ ovarian cancer. 
• Section G (ii): The family pedigree in this section can be filled by using the provided codes. The 
dotted lines can be filled if the extended family is known. (an explanation was done on page 7) 
• Section H: This section both of parts (H i and H ii) are only to be answered for the female 
participant. This section questions related to hormonal changes the female participant goes 
through, the age of menarche, menopause, and pregnancy period. We also would like to collect 
information regarding the uses of any hormonal treatment (contraceptive or HRT) through life. 
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•  Section I: This section we are asking if the participant ever had a regular checkup for the 
screening of breast cancer. The results of the mammogram BIRDS table are in the appendices of 
manual of operation of the LBCR on page 16, the doctor filling in the form can check reports and 
circle finding accordingly. 
e.g., If the participant has a regular checkup, the last mammogram reported: 
 
The finding is benign breast lesions, and there is no cancer appearance in the images of both 
breasts circle (II) for each site of the breasts. 
          (L) 0 I (II) III IV V VI Date: 19/ 07/ 2010. 
          (R) 0 I (II) III IV V VI Date: 19/ 07/ 2010. 
 
• Section J: Start taking information regarding the current breast cancer the 
participant was registered. The symptoms the participant had, the method of diagnosis. 
• Section K: Vital signs of the participant, also record the height and weight to calculate BMI. 
• Section L: Fill in the picture of the site of breast lesion diagnosed with breast cancer please 
indicate the site and lymph nodes if they were palpable. If there are any other scars or anomalies, 
please draw and indicate on the same picture. Please take time measuring all required sites of 
both upper limbs and fill in the measurement in centimeters. An explanation was provided on 
page 8 
• Section M: In this section, the participant will be sent to the breast cancer committee to decide 
the management plan. The full participant laboratory, histopathology staging, and metastasis 
work up are discussed with the surgical, radiologist, a medical oncologist. Please fill in the 
committee decision in the given space, type of plan the participant will receive. On page 17, the 
TNM classification can be checked. 
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• Section N: This section asks questions regarding the surgical procedure performed on the 
participant after diagnosis as part of the breast cancer management plan. The details of 
pathological staging must be filled from page 17. 
 
• Section O: As part of the participant work up this section includes the laboratory investigation, 
please fill in the last results of the participant workup before committee discussion 
• Section P: This section will be a continuation of participants work up for metastasis. Please fill in 
the given space of all types of scans and radiology tests performed 
• Section Q: This section of the ninth page collects information of the chemotherapy regime, the 
type of drugs received, the number of cycles advised, dates of both start and finishing 
chemotherapy. 
 
• Section R: This section will collect information regarding if the participant has received 
radiotherapy, the type of radiation the dose, and the site: document both starting and ending dates 
of treatment. 
 
• Section S: This section consists of the type of hormonal and target therapy offered to the 
participant. Please write the type of drug used, dose, the route given, started date, and when it was 
stopped. 
 
• Section T: If the participant taking any other medications not part of breast cancer management 
please document the type of medication. Also, if the participant is registered in a trial provide the 
name of trail. 
• Section U: This last section is for any comments or changes of information. The person 





8.II LBCR(II) FOLLOW-UP FORM 
• This part of LBCRF (ii) consists of seven pages. 
• The date of each visit must be filled, participant ID, code of ICD of breast cancer, and initials of 
person completing the form must be recorded for each visit. 
• Fill in the number of visit box specific for each visit. 
e.g., This is the third visit for the participant, fill the number 003 in the box. 
The number of visits: 
|_0_|_0_|_3_| 
• If the participant missed a visit, please indicate the reason and record the method of contact. 
• If the participant refused to continue, please indicate the date. 
• If after family members or hospital record indicates the participant has passed fill in the LBCR 
(iii). 
• Any changes in personal history, change location, new medical conditions, new imaging, 
laboratory results, or new procedures must be documented and updated. 
• Examination of participants' general appearance, site of previous primary cancer, and if there are 
any new changes must be added to provided space and drawn on the given picture. 
• Please measure both the upper limbs of the participant in each visit. 
• For the female participant, ask the age of menopause if the participant had a regular cycle at the 
time of diagnosis. 
• For female participant document if new pregnancies or procedure offered after starting cancer 
management. 
8.II LBCR (III) 
This part of the Libyan Breast Cancer Registry LBCR (iii) consists of two pages and has three sections. 
• Make sure the ICD specific for breast cancer, the ID of participant matching his information. 
Also, clarify if the participant is registered for more than one primary. 
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• The first section deceased details must be filled correctly from the hospital file; details from 
another source must be specified. 
• Fill in the date of death and age of deceased in the second section and his/her status of the last 
• contact from the LBCR (ii)/ Hospital files. 
• State the last results of an examination of the participant before death by choosing the appropriate 
disease status in section C. 
• If participant died due to other causes other than cancer secondaries or medication is taken for 
breast cancer, please specify. 
• A copy of the death certificate should be available. 
• State if there is any new information recorded, place of death, and autopsy reports. 
• If an autopsy was performed, fill-in the result and date. 
 
9. APPENDICES  

















9.1 TABLES  
 
9.1.1 Table T1: International standard classification of occupation 
 
Group 1: Legislators, senior officials and 
Managers. Legislators and senior officials’ 
Corporate managers. 
General managers, Businessman 
Group 7: Craft and related trade workers 
Extraction and building trade workers, Metal 
machinery and related trade workers, Precision 
hand craft and printing and related trades 
workers, 
Other craft and related trade workers 
Group 2: Professionals 
Physical, mathematical and engineering 
science 
associate professionals/ technicians, 
Teaching 
professionals, Other professionals. 
Group 8: Plant and machine operators and 
assemblers 
Stationary plant and related operators 
Machine operators and assemblers, Drivers and 
mobile plant operators 
Group 3: Technicians and associate 
professionals 
Physical, mathematical and engineering 
science 
associate professionals/ technicians, Life 




associated professionals/ technicians 
Group 9: Elementary occupations 
Sales and service elementary occupations 
Agricultural fisheries and related laboureres 
Laboureres in mining and construction 
manufactural and transport. 
Group 4: Clerks 
Clerks, Customer service clerks 
Group 10: Armed forces 
Armed forces 
Group 5: Service workers and shop and 
market 
sales workers 
Personal and protective services workers 
Models, salespersons and demonstrators 
Group 11: Homemaker 
Housewife/Househusband A women or a man 
who manage her/ his own household as 
his/her main occupation not merely an 
unemployed person. Need not necessarily 
be married 
Group 6: Skilled agricultural and fishery 
workers 
Market-oriented skilled agricultural and 
fishery 
workers, Subsistence agricultural and 
fishery 
workers. 
Group 12: Student 









9.1.2 Table T2: BIRDS classifications table 
BI-RADS I This score means an additional imaging is needed/ or incomplete image 
BI-RADS II This score results are negative for any signs of cancer 
BI-RADS 
III 




This score findings are suspicious lesions can be either:  
a- low suspicious for malignancy. 
b-  moderate suspicious for malignancy. 
c- high suspicious for malignancy 




The radiologist has already the diagnosis confirmed of malignancy. 
 
 
9.1.3  Table T3: Cytology FNA classification 
Code Microscopic findings 
C1 inadequate/ insufficient/ not-representative 
C2 Benign cells/ no evidence of malignancy 
C3 atypia/ indeterminate 
C4 suspicious of malignancy 

















9.1.4 Table T4: TNM clinical and pathological classification, (Breast Cancer TNM anatomical stage 
groups AJCC UICC 8th Edition). / Staging of breast cancer based on TNM. 




Tx unable to assess primary tumor 
T0 no primary tumor detected 
Tix type of primary tumor is carcinoma in situ, Tis (DCIS) = Ductal carcinoma in situ. 
OR Tis (Paget) = only the nipple without invasive carcinoma or DCIS lumps 
of the breast. 
T1 the size of tumor is not more than 20mm in greatest dimension. 
T1mi tumor size ≤1 mm in greatest dimension. 
T1a Tumor size >1 mm and less than 5 mm in greatest dimension 
T1b Tumor size >5 mm and less than 10 mm in greatest dimension 
T1c Tumor size more than 10 mm and not more than 20 mm in greatest dimension. 
T2 Tumor size more than 20 mm and not more than 50 mm in greatest dimension 
T3 Tumor size more than 50 mm in greatest dimension. 
T4 Tumor of any size with direct extension to the chest wall, with or without skin 
ulceration or macroscopic skin nodules. 
T4a Extension to chest wall, only include pectorals muscle without adherence or invasion 
to chest wall. 
T4b Ulceration and/or ipsilateral satellite nodules and/or edema including pea u d’ orange 
of the skin 
T4c Both T4a and T4b tumor. 














cNx Regional lymph nodes cannot be assessed, in case of previously removed by surgery. 
cN0
  
No regional lymph node metastases can be detected neither by clinical examination 
nor by imaging. 
cN1 Metastasis of tumor to the ipsilateral level I, II axillary lymph nodes, lymph nodes are 
mobile not fixed. 
cN1m cN1mi – Micro metastases (approximately 200 cells, larger than 0.2 mm, but none 
larger than 2.0 mm, in cases where sentinel node biopsy is performed before surgery 
cN2 cN2 – Metastasis of tumor to ipsilateral level I, II axillary lymph nodes. The lymph 
nodes are clinically fixed or matted. Also, when metastasis of tumor to the ipsilateral 
internal 
mammary nodes when clinically no evident of axillary node metastases at same side. 
cN2a Metastasis of tumor to ipsilateral level I, II axillary lymph nodes. The nodes are either 
fixed to one another or to other surrounding structures. 
cN2b Metastasis of tumor cells to ipsilateral internal mammary nodes, and in the absence of 
axillary node metastases clinically. 
cN3a Metastasis of tumor to ipsilateral infra-clavicular lymph nodes. 
cN3b Metastasis of tumor cells to ipsilateral internal mammary with clinical axillary lymph 
nodes involvement. 
cN3c Metastasis of tumor cells to ipsilateral supra clavicular lymph nodes with or without 
axillary or internal mammary lymph nodes. 
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pNX Regional lymph nodes cannot be assessed (eg, previously removed, or not removed 
for pathologic study). 
pN0 No regional lymph node metastasis identified or isolated tumor cells (ITCs) only. 
pN0(i+) Malignant cells in regional lymph node(s) no greater than 0.2 mm (detected by 
hematoxylin and eosin stain [H&E] or immunohistochemistry [IHC] 
pN0(mol 
+) 
 Positive molecular findings (reverse transcription polymerase chain 
reaction [RT-PCR]), but no regional lymph node metastases detected by histology or 
IHC. 
pN1 Micro-metastases, or metastases in one to three axillary lymph nodes, and/or 
clinically negative internal mammary nodes with micro- or macro-metastases 
detected by sentinel lymph node biopsy. 
pN1mi Micro-metastases (approximately 200 cells, greater than 0.2 mm, but none greater 
than 2.0 mm). 
pN1a Metastases in one to three axillary lymph nodes, with at least one metastasis greater 
than 2.0 mm. 
pN1b Metastases in ipsilateral internal mammary sentinel nodes, excluding ITCs. 
pN1c pN1a and pN1b combined 
pN2 Metastases in four to nine axillary lymph nodes, or positive ipsilateral internal 
mammary lymph nodes by imaging in the absence of axillary lymph node metastases 
pN2a Metastases in four to nine axillary lymph nodes (at least one tumor deposit greater 
than 2.0 mm). 
pN2b Metastasis only in clinically detected internal mammary nodes with or without 
microscopic confirmation; with pathologically negative axillary nodes 
pN3 Metastases in 10 or more axillary lymph nodes; or in infra-clavicular (level III 
axillary) lymph nodes; or in ipsilateral internal mammary lymph nodes by imaging in 
the presence of one or more positive level I, II axillary lymph nodes; or in more than 
three axillary lymph nodes and in internal mammary lymph nodes with micro-
metastases or macro-metastases detected by sentinel lymph node biopsy but not 
clinically detected; or in ipsilateral supra-clavicular lymph nodes. 
pN3a Metastases in 10 or more axillary lymph nodes (at least one tumor deposit greater 
than 2.0 mm); or metastases to the infra-clavicular (level III axillary lymph) nodes 
pN3b pN1a or pN2a in the presence of cN2b (positive internal mammary nodes by 
imaging); or pN2a in the presence of pN1b. 




M0 There is no evidence of metastasis using both clinical and radiological tests. 
cM0 
(i+) 
There is no evidence of metastasis using both clinical and radiological tests, 
microscopically less than 0.2 mm circulating tumor cells in blood or bone marrow 
and without present of tissue deposits. 
M1 Evidence of metastasis confirmed by both clinical and radiological tests, with 
presence of either circulating tumor cells more than 0.2 mm microscopically or 
proven histopathology tissue invasion. 
 
Stage Breast cancer staging based on TNM 
0 Tis, N0, M0 
 
I T1, N0, M0 
II A T0, N1, M0 or T1, N1, M0 or T2, N0, M0 
II B T2, N1, M0 or T3, N0, M0 
IIIA T0, N2, M0 or T1, N2, M0 or T2, N2, M0 or T3, N1, M0 or 
T3, N2, M0 
IIIB T4, N0, M0 or T4, N1, M0 or T4, N2, M0 
IIIC any T, N3, M0 
IV any T, any N, M1 
9.2 TEMPLATES  
• S1. The LBC Registry Form (i). 
• S2. The follow up / visit form of LBCR (ii). 
• S3. Deceased form of the LBCR (iii). 
• S4. Informed Consent: S4. a. Informed consent in the English language. S4. b. Informed consent 
in the Arabic language 
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LIBYAN BREAST CANCER RIGISTRY FORM(I)  
This form consists of 17 pages, please follow the manual of the LCRF and write with black pen. 
Consent form Must be signed before starting to fill the form. Check all pages are attached and 
participant ID is completed.  
Section A 
ICD-code C50 
Participant registry LBCR-ID:  |__|__|__|__|__|__|__|__|__|__| 
Specify if this is the first primary breast cancer (first file or second file for the same participant 
diagnosed with breast cancer. 
  First primary breast cancer. 
  Second primary breast cancer. 
If second primary, please fill the in the previous patient registry ID: 




Person filling the form details:  
Initial:  |__|__|__|                   Full name  
Cell phone number:                     Email address:                                            
Signature: _Date:  DD/MM/ YYYY 
 
Section C 
Details of participant Relative in case of required details: 
Full Name:                          Relation:  
Cell phone:                     Address:  
 
Section D -i 
Participant Details: 
Full name:                  Address (Town, village):  
City/Country Mobile (Telephone):  
Date of Birth:  DD /MM /YYYY.     Age:   |__|__|__|                                                                       
Country of birth:                          




LBCR (i) ID|_|_|_|_|_|_|_|_|_|_| C50                                                                                      Doctors Initials |_|_|_|      
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Section D -ii 
Marital status please fill in only one:                                     Participant nationality:       
  Never been married                                                     Libyan 
  Single                                                                           Not Libyan 
  Married                                                                        Un specified 




Specific for Libyan participant ONLY:                                Participant ID chose from below: 
  Arab                                                                                   Passport number 
  Amazigh                                                                             National number 
  Tuareg                                                                                Driver’s license                                                                                                    
  Tebow                                                                                 Family number 
 Un specified                                                                        Others, specify
                                                                                                                            ID Number:    |__|__|__|__|__|__|__|__|__|__|                                      
 Religion: 
 Muslim        Christian        Jewish        Hindu       Buddhist      Atheist         Unspecified 
Level of Education: (highest level of education).                     
  None (Illiterate)                                                                                         
  Primary school                                                                                        
  Secondary school/ high school                                                              
  Collage/ University or higher                                                                
  Unknown                                                                                                  
                                                                                                                                                                                                                       
Occupation of participant:                                                        Night shifts:     Yes            No                                  
Please Choose from table (1) from 1-12 |__|__|           If yes, years working night shifts: |__|__| 
        
Section E -i 
Participant personal habits                                              Number of years using tobacco:    |__|__|                                                             
Does the participant use tobacco products?                      Amount used per day: 
  Never had tobacco                                                 Less than 3 times a day    
  No                                                                           3-5 times a day                                    
  Yes.                                                                         more than 5 times a day                                  
If yes, please chose from below: 
  Sniffing                                                                   If participant Stopped using tobacco              
  Cigarettes                                                               Date stopped:  DD/MM/ YYYY                                
  Chewing                                                                                                              
  Narghile (Hookah) (Shisha)                             (The amount of tobacco: one cigarette/Pinch of        
  Other, Specify:                                powder for sniffing/ one session shisha) 
 
     
LBCR (i) ID|_|_|_|_|_|_|_|_|_|_| C50                                                                                  Doctors Initial|_|_|_|        
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Section E -ii 
Alcohol drinking (units =25 ml for spirit, ~175ml of wine, ~ 500ml of beer) 
  Never had alcohol                                                         If participant stopped drinking: 
  one unit a day                                                                Date stopped:  DD/MM/ YYYY                                
  < 3 units a day                                                               
  > 3 units a day 
 
         
Section E -iii   
Type of food   You can cross any type of food which is not consumed by the participant, choose from 
the amount of serving and amount served on daily basis from below)                                                                   
1          2            3        4 
□             □              □           □            Whole grain: pasta/ bread, barley couscous, brown rice, oat, rye                                                                          
□             □              □           □          Refined grain: pasta, bread, couscous, white rice                                                                                                      
□             □              □           □          Legumes(100gm): lentil/ chickpeas/ Pease /beans                                                                                   
 
□             □               □          □          Carbonated drinks, sweet packed juice                                                                                                 
□             □               □          □          Coffee/ Tea with sugar                                                                                                                                                      
□             □               □          □          Coffee/ Tea without sugar                                                                                                                                                
□             □               □          □          Snacks: cakes / biscuits/ chips/ sweets / chocolates                                                                                                       
 
□              □               □         □          Seasonal: fruits / vegetables / fresh juice (nuts or dates20-30g)  
□              □               □         □            Honey (1-2 t / spoons)   
□              □               □         □           Olive oil raw (2-3 t / spoons)                                                                                                          
 
□              □               □         □            Red meat cooked: Lamb, goat, camel, beef, cured meat                                                                                            
□              □               □         □            White meat cooked (Chicken / Fish / turkey, rabbit) Eggs                                                                                         
□              □                □        □            Animal fat/ ghee/ butter, cheese, full cream milk                                                                                                         
 
 
(Amount of food per serving: Meat= ~100 g, Bread=~ 4 slices or1/2 baguette, pasta/rice=~ 1/2 cup). 
 (1= 1-2 Times/Day   2= 2-3Times/Day   3= Once/Week       4= Never use this type of food) 
Does participant have any food allergy:    Yes            No    if yes specify:  
                      
Section E -iv 
Choose from below regarding participant exercise habits: 
  Never exercise 
  Minimal exercise, less than 1/2 hour a week 
  Exercise less than 3 times a week 
  Regular attends Gym more than 3 times a week 
 
  
  LBCR (i) ID|_|_|_|_|_|_|_|_|_|_| C50                                                                                  Doctors Initial|_|_|_|        
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Section E -v 
Choose from below regarding participant sleeping habits 
  
  Never takes afternoon naps  
  Takes regular afternoon naps daily 
   Not-interrupted night sleep 
   Interrupted night sleep. 
If participant has interrupted night sleep: Cause:  
If participant taking medication for sleeping
 
      
Section F-i 
Does the participant have a chronic medical problem (you can mark more than one)? 
  No 
  Yes 
If yes,  
  Chronic Vascular Disease       Diabetes Meletus      Psychiatric Disorder     HIV 
  Hypertension        Asthma       Parkinson      Liver Cirrhosis     TB 
  Congestive Heart Failure     Chronic Obstructive Pulmonary Disease     Alzheimer 
  Ischemic Heart Disease      Rheumatoid Arthritis       Dementia 
  Hypertension      Epilepsy     Osteoporosis     Depression     Epilepsy 
  Myocardial Infarction          Dyslipidemia          
   Other medical conditions, specify:  
 
Age of participant when diagnosed:  |_|_|_| 
If any medication taken: 
Date started taking medication; DD /MM /YYYY 
 
Does the participant have any drug allergy? 




Date of changes:  DD/MM/YYYY                   Initials: |_|_|_| 
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Section F- ii 
History of surgical procedure to the breast: 
  Needle biopsy                                                  Incision and drainage   
  Lumpectomy                                                   Breast Reconstruction  
  Breast Implant                                              Breast Reduction  
  Mastectomy                                                    Augmentation  
  Breast conserving surgery                             Micro-dochectomy  
  Breast Mastopexy (Breast Lift)                      Others, specify:…………. 
  Major duct excision 
                
 
Date (s) conducted:  DD/MM/YYYY Previous histopathology reports:  
Any history of chest trauma or radiation:   Yes     No  
 
If participant diagnosed with another primary breast cancer, please make sure noted in the first page 
of the LBCR (i) form. 
 
Section F- iii 
History of surgical procedure other than breast: 
Operation Date: DD/MM/YYYY  
Operation:  Date: DD/MM/YYYY 
Operation:  Date: DD/MM/YYYY  
Operation: __________________________ Date: DD/MM/YYYY 
Histopathology report results:  




Section F- IV 
History of diagnosis with Cancer (Not Breast) 
Site: ____________Date of diagnosis:  DD/MM/YYYYY 
Type: ____________________ 
Pathological stage:    T      N     M  
 
Did the participant receive any of the following? 
Surgery: ____________________________       Chemotherapy: _______________________ 
Radiotherapy: _________________________Others, specify: ________________________ 
Is the participant still on treatment? 
No          Yes 
If Yes, specify type of treatment: _________________ 
Started date:  DD/MM/YYYY 
Hospital /Centre Name: _________________________Unit / Department: _____________________ 
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Section G -i 
Family history of breast cancer                                            Genetic counseling done:                                         
  First degree                                                                       Yes         No                                                                       
  Second degree                                                             If yes: 
  Both                                                                                 BRACA 1             
Family members specify:              BRACA 2 
Age at diagnosis | __|__|__|                                                            Others:                                                            
                                                
 Family history of cancer (Not Breast)                                    Date performed: DD/MM/YYYY 
   First degree                                                                   Comments: __________________             
  Second degree    
Family members specify:  
Age at diagnosis | __|__|__|                                                                                                       
                                                                                                                                  
 
Section G -ii 
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Section H -i 
This section only for female participants if the participant is a male please go to Section I. 
Menarche age: |_|_|                                           Age of first pregnancy (Full term pregnancy): |_|_| 
Number of children:  |_|_|      G|___ P|___| (G= number of pregnancies, P= number of full-term deliveries)    
 
Did the participant breastfeed? 
  Yes             No 
 
If Yes, (answer for the longest duration the participant was breastfeeding). 
  Less than one year 
  Less than two years 
  Less than three years 
  More than 3 years 
 
Is the participant pregnant at the time of filling the form? 
  Yes             No 
 
If Yes, please answer the following:  
  first trimester (13 weeks) 
  second trimester (> 13- 21 weeks) 
  third trimester (>21- >36 weeks) 
Expected date of delivery: DD/MM/ YYYY 
 
If the participant currently breastfeeding with breast cancer: 
  Yes               No 
If yes: Date started breastfeeding DD/MM/ YYYY 
 
Any complications while breastfeeding: 
  Primary Breast cancer site  
  Contralateral site 
  Both breasts 
 
Type of breast complaints while breastfeeding at time of diagnosis with breast cancer (you can choose 
more than one answer). 
  Breast pain         Nipple fissure         Abscess          Lump          Change breast color 
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Section H – ii 
This section only for female participants if the participant is a male please go to Section I. 
Is participant Menopause at time filing the form: 
  Yes               No 
If Yes, Age of participant at Menopause: |_|_| 
 
Did participant use Hormonal Replacement Therapy (HRT): 
  Yes, currently on  treatment. 
  Yes, Stopped 
  Never 
 
If Yes, and still using how long the participant used HRT (circle the duration): |_|_| Years /   Months 
 
If the participant stopped using:  Date stopped: DD/MM/ YYYY 
 
Did participant use any type of contraceptives: 
  Yes            Never            On contraceptives. 
 
If Yes, or in treatment answer the following: 
  Oral tablets      Injections      Intrauterine hormonal device     Others, specify  
 
Name of contraceptive: ______________________      How long been used:  |_|_| / Years   Months 
 

















Does the participant have a regular breast self-examination (BSE)? 
  Yes               No 
 
Does the participant have a regular clinical breast examination by a Doctor (CBE)? 
  Yes                No 
Last ultrasound report if done at any age for screening of Breast cancer:  
 
0 I II III IV V VI       Date of Ultra-sound:  DD/MM/YYYY 
 
Did the participant ever have a mammogram at the age of 40 years or above? 
  Never 
  Yes, not regular mammograms examination 
  Yes, regular mammogram examination 
If Yes, please fill in the last mammogram date and result by circling BIRADS from Table I: 
 




History of current breast cancer. 
  Left Breast                     Right Breast                 Both Breasts 
 
Methods of detecting current breast cancer: 
  Unknown         BSE               CBE             Mammogram (Screening) 
 
How long since the symptoms started, and diagnosis was made fill-in the approximate number: 
  Days: |_|_|_|              Months: |_|_|              Years:  |_|_| 
 
Symptoms related to breast at diagnosis: You can mark more than one answer 
  No symptoms    Lump    Dimpling of the skin     Pain in the breast     Ulcer in breast 
    Breast changes in size       Nipple discharge (not blood)       Nipple bleeding    
  Changes of breast color      Nipple ulcer/ scaling   Others, specify:  
 
Diagnosis was performed by: 
  FNAB            Core needle         Incision biopsy             Excision biopsy 
  Others  
Cytology report of participant at diagnosis of Breast Cancer (Chose from table III and circle below 
result):      C1   C2   C3   C4    C5 
Histopathology report of participant at diagnosis of Breast cancer  
 
Receptor status at time of diagnosis (please write if the receptor positive/ negative): 
ER:                            PR:                           HER2:                                    Ki67: 
 
LBCR (i) ID|_|_|_|_|_|_|_|_|_|_| C50                                                                                  Doctors Initial |_|_|_|   
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Section K 
Vital signs of participant at visit: 
Blood pressure:|__|__|__|/|__|__|__| mmhg 
Pulse rate:|__|__|__| Beats/ minute 
Respiratory rate: |__|__|__| Breath/minute 
Weight: |__|__|__|. |__| Kg 
Hight: |__|__|__|. |__| cm 
 
BMI =               body weight in kg____________           
      (body height in meters) x (body weight in meters) = |__|__| 
 
Please chose one result from BMI below: 
  Underweight < 18.5         Normal 18.5 - 24.9            Overweight 25 - 29.9        Obese > 30 
 
Status of participant at time of diagnosis: 
  Looks healthy           Looks ill, Walking                       Looks ill, in a wheelchair      
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Section M 
Breast Cancer Multidisciplinary Team Decision: 
 
Date     DD/MM/YYYY 
 
Section N -i 
Surgical procedures: 
  Yes               No              Patient refused                     Participant not fit for surgery 
Reason not fit:  
 
If participant not fit for sergery/ refused do not continue and move to section O. 
 
 
Breast Primary tumor site 
 Left        Right        Both         Others, specify
Types of tissue removed: 
 Type of operation primary site(A) 
  Lumpectomy               BCS/ Partial mastectomy              Simple mastectomy         
  Mastectomy+ Axillary clearance          Axillary clearance only             Axillary sampling     
  SLN                Breast Reconstruction                                  Others, specify  
Lab specimens’ number: |_|_|_|_|_|_|_|_|_|_| Date of operation:  DD/MM/YYYY 
 
 Type of operation primary site(B) 
  Lumpectomy               BCS/ Partial mastectomy              Simple mastectomy         
  Mastectomy + Axillary clearance          Axillary clearance only             Axillary sampling     
  SLN          Breast Reconstruction                                 Others, specify: __________                     
Lab specimens’ number: |_|_|_|_|_|_|_|_|_|_| Date of operation:  DD/MM/YYYY 
 
 
 Type of operation primary site(C) 
  Lumpectomy               BCS/ Partial mastectomy              Simple mastectomy         
  Mastectomy +Axillary clearance          Axillary clearance only             Axillary sampling     
  SLN            Breast Reconstruction                                   Others, specify:                      
Lab specimens’ number: |_|_|_|_|_|_|_|_|_|_| Date of operation:  DD/MM/YYYY 
 
 Type of operation primary site(D) 
  Lumpectomy               BCS/ Partial mastectomy              Simple mastectomy         
  Mastectomy + Axillary clearance          Axillary clearance only             Axillary sampling     
  SLN          Breast Reconstruction                                    Others, specify:                      
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Section N - ii 
Breast Primary Tumor Type:                                            Type of Noninvasive Primary of the Breast: 
  Invasive          Noninvasive                                   DCIS            LCIS 
 
Type of Invasive Primary Tumor of Breast Cancer: 
  Ductal     Lobular      Medullary      Mucinous     Tubular     Mixed      Inflammatory 
 
   Papillary      Paget’s       Malignant Phyllode        Others, specify:  
 
Measurement of primary tumor (A) 
Size of invasive tumor: _ mm X   __ mm X _ mm 
Size of In-situ: __   mm X   __   mm X   __    mm 
Size of total lesion:  __mm X __   mm X _    mm 
 
Measurement of primary tumor (B) 
Size of invasive tumor: _ mm X   __ mm X _ mm 
Size of In-situ: __   mm X   __   mm X   __    mm 
Size of total lesion:  __mm X __   mm X _    mm 
 
Measurement of primary tumor (C) 
Size of invasive tumor: _ mm X   __ mm X _ mm 
Size of In-situ: __   mm X   __   mm X   __    mm 
Size of total lesion:  __mm X __   mm X _    mm 
 
Measurement of primary tumor (D) 
Size of invasive tumor: _ mm X   __ mm X _ mm 
Size of In-situ: __   mm X   __   mm X   __    mm 




  Well differentiated              Intermediate differentiated             Poorly differentiated 
 
Lymph node Biopsy/ Clearance: 
  Axilla of primary breast cancer site        Axilla of ipsilateral primary breast cancer site 
  Supra clavicular primary breast cancer site      Internal mammary primary breast cancer site 
  Supra clavicular of opposite site primary breast cancer        Others, specify  
 
Method detected Lymph Nodes/ Sentinel Lymph Nodes 
  Palpation/ Surgical removal axillary fat only                Blue dye /Biopsy only 
  Isotope/ Biopsy only               Both blue dye and isotopes /Biopsy 
  Axillary fat removal with both blue dye and Isotope               Unknown 
 
Number of nodes detected/Removed:  |_|_|_| 
Number of lymph node involved with cancer:  |_|_|_|  
Lymph Nodes with Extra capsular invasion:  |_|_|_| 
Date:  DD/MM/YYYY 
Receptor status: 
  ER: _______       PR: ________         HER2 /neu: _______________       
 
TNM Stage (pathological stage):         T    N     M   |__|__|__| 
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Section O 
Laboratory examination: Please fill in the latest results only. 
 
Tumor markers: 
CEA _______          ng/ml. Date:  
Ca 15-3 __________U/ml. Date:  
Ca 27.29   ________U/ml.  Date  
Ca 125 ___________U/ml Date:   
Others specify:                   Date:   
Full blood count (FBC) 
Hemoglobin_________       Date:  
WBC_____________           Date:  
RBC_____________          Date:   
Platelets________             Date:   
Other specify: ______        Date  
Liver function test (LFT): 
Serum bilirubin
ALT (SGPT) ___________Date:   
AST (SGOT) ___________Date:   
Albumin__________          Date:   
PT/INR___________         Date  
TP______________           Date:   
LDH__________                Date:   
Other specify: _______     Date:   
 
Renal function test (RFT): 
GFR ________________   Date:  
Creatinine_________         Date:   
Blood urea ___________   Date:  






Other tests specify/result: 










LBCR (i) ID|_|_|_|_|_|_|_|_|_|_| C50                                                                                  Doctors Initial|_|_|_|   
 34 
Section P 
Metastatic Workup (fill only the last results): 
Latest Mammograms:  
  Left           Right 
Please circle the appropriate BIRADS for each breast chose details from table 2. 
 
L       0 I II III IV V VI    Date: 
 
R      0 I II III IV V VI     Date: 
 
 
Ultrasound examination: Breast/ Axilla                         Ultrasound examination: Abdomen/ Pelvis: 
Left____________________________                            Results: __________________________ 
Right___________________________                             ___________________________ 
 
Date Date:   
 
X-rays examination (1):                                                        X-rays examination (2): 
Site: ____________________                                              Site: ____________________ 
Result: ____________________                                          Result: ____________________ 
Date:  Date:  
 
 
Computed tomography CT scan (1):                                 Computed tomography CT scan (2): 
 
Site: ____________________                                             Site: ____________________ 
Result: __________________________                            Result: _______________________ 
Date:                                                         Date
 
MRI (Magnetic Resonant Imaging)                                 Others investigation:                               
Site: ____________________________                            Site: ________________________ 
              




PET scan (Position Emission Tomography)                  Comments:_____________________   
Result: ___________________________                        ________________________________ 
Date: DD/MM/YYYY                                                         _______________________________ 
 
Bone Scan (Scintigraphy)                                                Date:DD/MM/YYYY   Initials:|_|_|_| 
Result: ______________________ 








  Yes               No              Patient refused                     Participant not fit for Chemotherapy 
Reason not fit  
 
If participant not fit for chemotherapy / refused, do not continue and move to section R 
 
Type of chemotherapy given (regime)   
  Before surgery partial cycle 
  Before surgery full cycle 
  Post-surgery partial cycle 
  post-surgery full cycle 
  Palliative 
 
Number of cycles before surgery:  |_| _|                              Number of cycles after surgery:  |_|_| 
 
Name of drugs                                                        Route   Dose            Start Date         Stopped Date
  
  ______________________________________________  
  _______________________________________________  
  _______________________________________________   
  ______________________________________________            
  ______________________________________________  
  _______________________________________________          
  _______________________________________________  
  ________________________________________________        
  ________________________________________________         
  ________________________________________________  
 
 





Date:DD/MM/YYYY   Initials:|_|_|_| 
 
 





  Yes               No            Patient refused                 Participant not fit for Radiation therapy 
 
Reason not fit: _______________________ 
 
Type of management: 




  Breast of primary cancer before surgery                            Supra clavicular  
  Breast of primary cancer post-surgery                                Chest wall  
 Axillary same site of primary breast cancer                       Others, specify: 
Date received Radiotherapy:  
Date stopped Radiotherapy:   
 
Section S 
Hormonal therapy/ Target therapy received: 
Hormonal Therapy 
  Yes                  No              Participant refused                Participant not fit. 
Reason not fit
Hormonal treatment type: 
  Ovarian ablation by radiotherapy                                    Medication. 
 Oophorectomy (surgical removal of ovaries)                  Others, specify: 
 
If participant used any medication:     Before surgery      After surgery 
 
Name of drugs                                                             Route Dose         Start Date         Stopped Date
   
  _  
   
  _   
Target Therapy 
  Yes                  No              Participant refused                Participant not fit. 
Reason not fit  
If yes, therapy started:    Before surgery      After surgery 
 
Name of drugs                                                             Route Dose         Start Date         Stopped Date
   
  _  
  _  
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Section T 
Any other medication prescribed: 
 
Name of drugs                                                             Route Dose         Start Date         Stopped Date
   
  ___  
  _  
 
 
Any other used not prescribed treatment by the participant: 
  _  
  _  
 
 






Any change of information please use this space and fill-in the initials and date. 
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LIBYAN BREAST CANCER RIGISTRY FORM (II)  
This form consists of SEVEN pages, please follow the manual of the LCRF and write with black pen. 
Check all pages are attached and participant ID is completed.  
Section A 
Visit number: |__|__|__|__|__|                                 Date of visit: DD/MM/YYYY 
 
Participant LBCR- ID: |__|__|__|__|__|__|__|__|__|__|__|__| C50 
 
Person filling the form details/ initials: 
Full name:                                Initials:   |__|__|__| 
Place of work:                                 Telephone number:                                            
 
If participant changed any contact details, please fill in below: 




Participant details for attending visit: 
  Participant attended visit as scheduled date 
  Participant attended unscheduled visit 
  Participant attended after contact was performed by hospital staff 
  Participant did not attend after contact was performed by hospital 
 
Indication for visit: 
  Visit to receive treatment                     New complaint                    Routine check up 
Reason of unscheduled visit/ New complaint:  
 
If Participant attended visit move to section C. If not continue answering Section B. 
 
  An attempt was made to contact the participant by registry team. 
  An attempt was made to contact family member by registry team. 
  Participant replied. 
  Family member replied 
 
Reason of not attending:
 








Does the participant have a new primary breast cancer? 
  Yes             No 
If yes answer Section D for both sexes. 
If no and the participant is a female with no new primary breast cancer answer Section E.  




Only fill this section if the participant has a new primary breast cancer: 
New primary breast cancer site: 
  Contralateral (Opposite side) 
  Ipsilateral (same side) 
Histopathology report:  
Date of result:   DD/MM/YYYY 
Please fill a new form for the new primary breast cancer and complete the following: 




For female participant ONLY at visit: 
  No pregnancy 
  Menopause 
  Pregnant after diagnosis and treatment 
  Pregnant and receiving treatment 
  Miscarriage/ Abortion while on treatment 
  Miscarriage/ Abortion after treatment 
  Delivered after treatment 
  Delivered while on treatment 
  Others specify  
 
Age started menopause if participant was not menopause at start of treatment: |__|__| years. 
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Section F 
Change in personal habits after diagnosis/ management/ last visit: 
Regular eating:  
  Yes                             No, reason: ________________________________________ 
 
Regular night sleep:  
 Yes                            No, why
 
Returning to normal activity (work, socializing):  
  Yes                           No, why  
 
Change in sexual activity:  
  Yes, specify:        No 
 
Using of alternative medicine (herbs, spiritual)  







  participant apparently well                       participant sick/weak/walking 
  participant on wheelchair/unable to walk without help                   Participant bed ridden 
 
Vital signs of participant at visit: 
Blood pressure:|__|__|__| / |__|__|__| mmhg 
Pulse rate:|__|__|__| Beats/ minute 
Respiratory rate: |__|__|__| Breath/minute 
Weight: |__|__|__|__|__| Kg 
 
Clinical examination: 
  No evidence of disease         local recurrence 
  New primary breast cancer             Metastasis without local recurrence 
  Metastasis with local recurrence             Lymphedema 
 Others specify: 
 
If participant has metastasis the diagnosed method was: 
  Clinical                      Imaging                   Cytology               Histopathology. 
 
   Results/ Site:                           Date: DD/MM/YYYY 
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Section H 
If participant has Lymphedema 
  Movement of arm not disrupted           No movement (difficult / pain). 
 
Methods of diagnosis: 
  Clinical                 Measurements                       Scans 
 
Methods used in management lymphedema: 
  Bandage/ Compressor garment          Exercise/Massage therapy      Manual lymph drainage 
  Surgery/Laser                       Others:  
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Section I 
Laboratory examination: Please fill in the latest results only. 
 
Tumor markers: 
CEA _______          ng/ml. Date:  
Ca 15-3 __________U/ml. Date:  
Ca 27.29   ________U/ml.  Date  
Ca 125 ___________U/ml Date:   
Others specify:                   Date:   
Full blood count (FBC) 
Hemoglobin_________       Date:  
WBC_____________           Date:  
RBC_____________          Date:   
Platelets________             Date:   
Other specify: ______        Date  
Liver function test (LFT): 
Serum bilirubin
ALT (SGPT) ___________Date:   
AST (SGOT) ___________Date:   
Albumin__________          Date:   
PT/INR___________         Date  
TP______________           Date:   
LDH__________                Date:   
Other specify: _______     Date:   
 
Renal function test (RFT): 
GFR ________________   Date:  
Creatinine_________         Date:   
Blood urea ___________   Date:  






Other tests specify/result: 
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Section J 
Visit Workup (fill only the last results): 
Latest Mammograms:  
  Left           Right 
Please circle the appropriate BIRADS for each breast chose details from table 2. 
 
L       0 I II III IV V VI    Date: 
 
R      0 I II III IV V VI     Date: 
 
 
Ultrasound examination: Breast/ Axilla                         Ultrasound examination: Abdomen/ Pelvis: 
Left____________________________                            Results: __________________________ 
Right___________________________                             ___________________________ 
 
Date Date:   
 
X-rays examination (1):                                                        X-rays examination (2): 
Site: ____________________                                              Site: ____________________ 
Result: ____________________                                          Result: ____________________ 
Date:  Date:  
 
 
Computed tomography CT scan (1):                                 Computed tomography CT scan (2): 
 
Site: ____________________                                             Site: ____________________ 
Result: __________________________                            Result: _______________________ 
Date:                                                         Date
 
MRI (Magnetic Resonant Imaging)                                 Others investigation:                               
Site: ____________________________                            Site: ________________________ 
              




PET scan (Position Emission Tomography)                 Comments:_____________________   
Result: ___________________________                        ________________________________ 
Date: DD/MM/YYYY                                                         _______________________________ 
 
Bone Scan (Scintigraphy)                                               Date:DD/MM/YYYY   Initials:|_|_|_| 
Result: ______________________ 
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Section K 





Advice of visit: 
Follow up:               Yes           No 
 
If yes, date of next visit: DD/MM/YYYY  
 
New or Change of Treatment:  
  Yes            No  
If yes, specify Drug/Dose  
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LIBYAN BREAST CANCER RIGISTRY FORM(III)  
This form consists of TWO pages, please follow the manual of the LCRF and write with black pen. 
Check all pages are attached and participant ID is completed.  
Section A 
Person filling the form details/ initials:  
Full name Initials |__|__|__| 
 
Place of work:  
Date of filling the form:  DD/MM/YYY 
 
Participant registry of first primary breast cancer: 
LBCR-ID |__|__|__|__|__|__|__|__|__|__|__|__| 
 
Participant registry of second primary breast cancer: 
LBCR-ID |__|__|__|__|__|__|__|__|__|__|__|__| 
 
Source of information: 
 Hospital records        Relative                Others specify: 
 
If participant has changed address before death, please fillin the new address: 
New Address         City  




A copy of the death certificate must be in the file of deceased. 
Date of death: DD/MM/YYYY               Age at time of death: |__|__|__| 
 
Status of last contact: 
  Apparently well  
  On wheelchair 
  Bed ridden 
  Others, specify  
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Section C 
Disease status at time of death: 
  No evidence of disease at time of death 
  there is local recurrence of cancer (lump/fungating mass)  
  metastatic to opposite breast 
  metastasis to other parts of body 
  death while performing surgery 
  death while receiving chemotherapy  
  death while receiving radiotherapy 
 
If there was metastasis, please fill in the site
If a histopathology was performed/results/site  
TNM time of death: T |__|   N |__|   M |__| 
 




Cause of death: 
  Unknown 
  Death due to primary cancer 
  Death related to other cancer 
  Death not related to cancer 
 
Death not related to cancer please specify  
Autopsy was performed         Yes           No 
If yes, please write findings Date of autopsy: DD/MM/YYYY
 
Any comments/ changes: 
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LIBYAN BREAST CANCER RIGISTRY CONSENT FORM  
Please read/listen to the information before signing the form: 
• Why do I need to register? 
We are recording all breast cancer patients in the country by collecting your data from all 
medical records. We will be using your personal, laboratory, imaging results treatment that you 
have received and follow up list records. The purpose of registration is to calculate the number of 
patients with breast cancer, to help investigate the possible causes of the disease and distribution, 
occurrence in specific groups, also related risks that can aggravate the breast cancer. This 
registry will not affect your treatment, there will be no change in your treatment plan as advised 
by your specialist. 
• Are there any risks or disadvantages for me? 
There will be no risks or any disadvantages from registering; we only need your detail data 
regarding diagnosis and treatment. 
• Are there any benefits for me? 
There are no additional benefits for you or any other participant, and there will be no payment 
for all participants taking part in the registry. You will be treated no difference to anyone who 
does not take part this registration.  
• What if I would like to stop to participate? 
You are free to participate and decide to withdraw at any time and not to complete the follow-up 
forms. If you miss any fallow-up, an attempt will be made to contact, you or your relative to 
 48 
remind you. Your follow- up, management, and care will not change from any other participant 
and will continue as advised by your specialist now and in the future. 
• Who will have access to my information? 
All data will be stored and de-identified. The investigators only have access to the coding. Any 
additional staff or researches will see your data without your name details.  
In case of a missed visit, an attempt to call you or your documented relative for further 
information needed, and this information will be recorded (written) to your form. 
• You are free to ask any questions at any time.  
Dr. Muna AB Owen Abulkasim 
Tel: 061 070 1366 











LIBYAN BREAST CANCER RIGISTRY CONSENT FORM  
Please read/ Listen 
I have read/ listen and understood the above information, and all my questions have been 
answered. I understand I was selected to participate and have the right to withdraw at any time. I 
will receive my full treatment as advised by my oncologist in case I would like to discontinue in 
providing any personal information. I am aware that my information will be used in medical 
research for education purpose in an attempt to help patients suffering from breast cancer. I agree 
to allow my results to be published in medical journals or books and will be available at the 
Universities for public use. 
Participant full name:
Date:  DD/MM/YYYY                                                 Signature/ Fingerprint
In case of the participant cannot write or read: 
Name of person                                    Relation                     
 Date: DD/MM/YYYY          Cell phone: Signature:  
Name of witness
Date: DD/MM/YYYY                                                         Signature
The person completing the form: 
Place of work Cell phone:
Date: DD/MM/YYYY    Email address:                      Signature
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يدثلا ناطرس لیجستلا ىلع ةقفاوملا   ةرامتسا
لیجستلا لبق ةماھ تامولعم  
 
؟لیجستلل جاتحأ اذامل  
 ربتخملا جئاتن( ةصاخلا ةیبطلا تالجسلا عیمج نم ةیصخشلا كتانایب عمج لالخ نم دلبلا يف يدثلا ناطرس يضرم عیمج لجسن نحن
 يف ةدعاسملل يدثلا ناطرس نم نوناعی نیذلا يضرملا ددع ةفرعم وھ لیجستلا نم ضرغلا )ةعباتملا تالجسو ةعشألاو ریوصتلا جئاتن
    اذھ رثؤی نل .يدثلا ناطرس مقافت يلا يذؤت نا نكمی يتلا ةلصلا تاذ رطاخملا كلأذكو ،ھثودحو ھعیزوتو هراشتنا بابسا قیقحتلا
صتخملا كبیبط لبق نم حضوم وھ امك جالعلا ةطخ يف ریغت يا كانھ نوكی نلو كجالع ىلع لجسلا  
 
؟يل ةبسنلاب رطاخم يأ كانھ لھ  
جالعلاو صیخشتلاب قلعتی امیف كب ةصاخلا تانایبلا طقف جاتحن لیجستلا نم رطاخم يأ كانھ نوكی نل . 
 
؟يل دئاوف يأ كانھ لھ  
 يف قرف كانھ نوكی نل لیجستلا يف نیكراشملا عیمجل تاعوفدم يأ كانھ نوكی نلو رخآ كراشم يأل وأ كل ةیفاضإ دئاوف دجوت ال
لیجستلا اذھ يف كراشی ال صخش يأ عم لماعتلا  
 
؟ةكراشملا نع فقوتلا يف بغرأ تنك ول اذام  
 ةلواحم متتسف ةعباتم يأ كتتاف اذإ .ةعباتملا جذامن لامكإل تامولعم يأ ءاطعإ ضفر يف قحلاو تقو يأ يف باحسنالا يف قحلا كیدل 
لبقتسملا يفو نآلا صتخملا كبیبط لبق نم ھیلع صوصنم وھ امك رمتستسو ةیاعرلاوأ ةعباتملا ّریغتت نل .كریكذتل كب لاصتالا . 
 
؟يتامولعم ىلإ لوصولا قح ھیدل نوكیس نم  
     ةیناكمإ طقف مھیدل نم مھ لیجستلا ةدحو يف نولمعی نیذلا لیجستلا نع نیلوؤسملا صاخشألاو زومرب تانایبلا عیمج نیزخت متیس
   تامولعملا نم دیزم ىلع لوصحلل براقالا برقأ وأ كب لاصتالا لواحنس بیبطلا ةرایزل كروضح مدع ةلاح يف زیمرتلا ىلإ لوصولا
كب صاخلا جذومنلا يلا تامولعملا هذھ لیجست متیسو ،ةبولطملا   
 
: راسفتسالا و ةلئسألا نكمی   
مساقلا وبا نوع مالسلا دبع ينم .د   








عامتسالا وا ةءارقلا يجری  
 يف قحلا يدلو ةكراشملل يرایتخا مت دق يننا مھفاو ،يتلئسأ عیمج ىلع ةباجالا تمتو ،هالعا ةدراولا تامولعملا تمھفو تعمتسا/تارق دقل 
 نا كردأ .ھیصخش تامولعم يا میدقت نع فقوتلا يف تبغر لاح يف ماروالا بیبط ھب مدقت يذلا لماكلا جالعلا يقلتا فوسو ،تقو يا يف باحسنالا
 تالجملا يف يجئاتن رشنب حامسلا ىلع قفاواو .يدثلا ناطرس نم نوناعی نیذلا يضرملا ةدعاسمل ةیملعلاو ةیبطلا ثاحبالا يف مدختستس تامولعملا
ماعلا مادختسالل تاعماجلا يف ةحاتم نوكتسو ةیبطلا بتكلا وا  
                                                                                                                                        : لماكلاب كراشملا مسا   
: خیرات                                         : عیقوتلا  : ةمصب   
: ةءارقلا وأ ةباتكلا نم كراشملا نكمت مدع ةلاح يف   
كراشملاب صخشلا ةقالع    :                                                                    : صخشلا مسا   
: خیرات  عیقوتلا                                        فتاھلا مقر                                                                   
: دھاشلا مسا   
: خیرات                                                         : عیقوتلا   
 
تانایبلا ذخأب ماق يذلا صخشلا مسا  
لمعلا ناكم                                             : يولخلا فتاھلا   
: ينورتكلا دیرب ناونع   
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THESIS CONCLUDING REMARKS 
  
Chapter 6          2 
THESIS CONCLUDING REMARKS 
 
Breast cancer incidence and mortality differ across regions and between sexes; however, it 
remains the most familiar diagnosed cancer in women and one of the leading causes of cancer 
deaths across all continents.  
 
Principal findings 
First, the findings of this thesis have addressed the prevalence of breast cancer in Africa. We 
propose that it serves as a resource for providing baseline figures for future local and national 
comparisons. 
Second, this report on the design of the Libyan Breast Cancer Registry includes ready and 
accessible information to serve as a template for present and future use of medical elements and 
researchers in the field of science. 
 
Implications for policy and future research 
Growing incidence and mortality rates of breast cancer in Africa provide clear evidence that this 
part of the world does not yet have an appropriate management strategy. In consideration of the 
above, African countries should embark on awareness and early prevention of the disease, 
through proper identification methods and reduced exposure to established risk factors in 
conjunction with appropriately-sensitive and highly specific diagnostic methods for young adults 
and advance suitable treatments.  Coupled with a high quality registry, such as the Libyan Breast 
Cancer Registry, will provide meaningful evidence for the control of breast cancer in Africa and 
will have an unquantifiable effect on the national development of African countries. 
 
